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ABSTRACT 
Diabetic Kidney Disease (DKD) is a major complication of diabetes. Incomplete understanding of 
its molecular mechanisms is highlighted by the limited treatments options. We hypothesized that 
inhibition of protective endogenous mechanisms plays major role in the pathogenesis of 
DKD.  While renoprotection is mediated by cyclic nucleotides (cAMP and cGMP), 
phosphodiesterases (PDEs) lead to cyclic nucleotide degradation. Our investigation focused on the 
role of calcium/calmodulin activated PDE1 in DKD. Three isoforms of PDE1 are differentially 
expressed in vascular smooth muscle cells, renal tubular epithelial cells, podocytes, and mesangial 
cells. We used highly potent and selective PDE1 inhibitor LY1 to explore systemic hemodynamic 
and local renal role of PDE1. LY1 reduced systolic and diastolic blood pressure in normotensive 
and spontaneously hypertensive rats.  Renal protection with PDE1 inhibition was tested in mouse 
model of DKD, featuring a combination of diabetes, nephron loss and arterial hypertension. In this 
model, a PDE1 inhibitor caused a significant improvement in renal function as evident by 
significant reduction of albuminuria, serum creatinine and several urine biomarkers of 
inflammation and injury. Histopathological analysis revealed substantial improvement in the 
pathology of DKD in the treated group that was associated with the reduction of gene expression 
related to inflammation and fibrosis. Thus, we revealed the role of calcium activated PDE1 in 
DKD. However, the source of calcium in this context remained obscure. Our bioinformatics 
analysis pointed out that calcium channel TRPC6 is likely to be involved. Further in vitro studies 
demonstrated that TRPC6 activation induced apoptosis in human mesangial cells and isolated rat 
glomeruli, which was attenuated by both TRPC6 and PDE1 inhibition, thereby suggesting a 
functional coupling between TRPC6 (as a source of calcium) and PDE1 activation. Moving 
upstream, we showed that several systemic risk factors of DKD (angiotensin II, endothelin 1 and 
glucose) activated TRPC6 in a different manner, through generation of either reactive oxygen 
species or diacylglycerol. The computational modeling to relate human transcriptomic and 
phenotype data demonstrated the pre-clinical findings of renal benefit upon PDE1 inhibition is 
translatable in human. Taken together, our results suggest mechanistic link among systemic risk 
factors, TRPC6, calcium flux and PDE1 activation in pathogenesis of DKD. As a corollary, PDE1 
inhibition leads to direct and indirect renoprotective effects. 
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 DIABETIC KIDNEY DISEASE: CHALLENGES AND 
POTENTIAL NOVEL MECHANISM 
1.1 Introduction 
Diabetic Kidney Disease (DKD) is a microvascular complication of both type I and type II diabetes 
mellitus which often results in end-stage renal disease (ESRD) requiring either dialysis or renal 
transplantation. [1]. Patients with DKD have a high rate of mortality, high financial burden, as well 
as a very poor quality of daily life. Prevalence rates of DKD are increasing in parallel with the 
incidence rates of diabetes mellitus. Currently in the United States (US) about two hundred 
thousand patients receive ESRD care due to DKD, with fifty thousands new patients starting 
dialysis each year [2] and it is estimated that by 2030 the number of DKD patients will increase 
significantly due to the projected 54% increase in the prevalence of diabetes [3]. Primarily the 
increased prevalence of obesity, metabolic syndrome, and westernization of lifestyle are the 
drivers of diabetes but to what extent these factors contribute to DKD remains unknown. Clinically, 
a diabetic patient with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 
m2 and/or albuminuria greater than 30 mg/g creatinine would be diagnosed with DKD [4]. In the 
clinic angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB), 
the widely used blood pressure lowering drugs, are the current standard of care for DKD. But 
unfortunately, they can achieve only 20% reduction in risk of future ESRD, rendering it semi-
effective option for the DKD patients [5]. Moreover, even with the best available clinical 
management, involving both glycemic and blood pressure control, it is only possible to achieve at 
most a 30% improvement in declining diabetic kidney [6-8]. In recent years the successful clinical 
trial of SGLT2 inhibitor and GLP agonist provided new therapeutic opportunity but still there is 
an urgent need for new interventions that will effectively delay or reverse CKD progression in 
patients with diabetic nephropathy (DN). To facilitate the discovery of new intervention 
understanding of the disease mechanism is crucial. The pathophysiology of DKD complex and 
multifactorial, that involves both genetic and environmental factors. The exact mechanism is not 
well understood. Although the initial trigger is hyperglycemia but in later stages several risk factors 
like obesity, hypertension, etc. contributes towards the progression of the disease. Although these 
risk factors are clearly important, the exact mechanism is still unknown. The mechanistic 
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understanding of how the systemic risk factors like high glucose, or other co-morbid factors 
translate into downstream intracellular signaling pathway and identifying the key players would 
provide new therapeutic opportunity for DKD. 
1.2 Risk factors for diabetic kidney disease 
Initially, hyperglycemia driven pathogenic pathways act as trigger but later the interaction of 
metabolic and hemodynamic factors plays a major role in the progression of the disease [2, 9]. 
These metabolic factors such as excess fatty acids, glucose etc resulted in enhanced oxidative stress, 
formation and buildup of advanced glycation end-products (AGEs) and renal polyol formation. 
The hemodynamic factors include both increased systemic and intraglomerular pressure, in 
addition to the activation of vasoactive hormone pathways including the renin angiotensin system 
and endothelin-1signaling pathways [10]. In the presence of chronic diabetes, both of these factors 
feed into and triggers common pathogenetic mechanisms that ultimately lead to increased renal 
albumin permeability resulting in proteinuria and extracellular matrix deposition resulting in 
glomerulosclerosis and ultimately tubulointerstitial fibrosis. 
1.2.1 Hemodynamic factors  
Hemodynamic factors like increased systemic blood pressure and intraglomerular pressure driven 
by the activation of several vasoactive hormone pathways like renin angiotensin system and 
endothelin-1 are major contributors to the disease [10].]. The role of hemodynamic factors in DN 
was emphasized first by Brenner et al, when they observed several intrarenal abnormalities 
including increased intraglomerular pressure, increased single nephron GFR and preferential 
vasodilation of the afferent, over the efferent, arteriole through micropuncture studies in diabetic 
rats. In the same study they also demonstrated that ACE inhibitor reduced intraglomerular pressure 
that is associated with reduced renal injury, thereby emphasizing the role of renin-angiotensin 
system (RAS) in DN. Moreover, in an in vitro system, glucose has been shown to upregulate 
angiotensinogen (converts renin to angiotensin II) in proximal tubular cell [10] and in mesangial 
cell stimulated angiotensin II production that is associated with increased TGFb accumulation [11]. 
However, the role of RAS in DN still remains somewhat controversial as plasma measurement of 
various components of RAS showed low to normal in diabetes, although the distribution of these 
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components in various compartments cannot be ruled out. Moreover data demonstrating renal 
benefit in both diabetic and non-diabetic model of renal injury by modulating TGFb expression 
and a range of intracellular mediators like PKC and NF-kB indicate some non-hemodynamic 
component of RAS system [10, 12]. In addition to angiotensin, several other vasoactive hormones 
like Endothelin-1, vasopressin has been attributed to the renal injury. These hormones have been 
shown to have differential effects on efferent and afferent arterioles thereby affecting the 
intraglomerular pressure. Recent success with Atrasentan, an endothelin-1 inhibitor, in DKD 
patients (SONAR trial), clearly emphasize the role of local hemodynamics in DKD [13]. Contrary 
to vasoconstrictors, a wide range of vasodilatory substances like bradykinin, atrial natriuretic 
peptide, certain prostaglandins, and nitric oxide have been shown to modulate glomerular vascular 
tone [10]. Neutral endopeptidase (NEP) is an enzyme that degrades natriuretic peptides as well as 
 
 
Figure 1.1. Schematic outlining interactions between hemodynamic and metabolic factors 
and how their interactions trigger the downstream signaling system in mediating diabetic 
kidney disease.                                                                                                                 Modified from Copper et al. 2001. 
 
 
bradykinin and endothelin converting enzymes. Combination of NEP inhibitor and ACE inhibitor  
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in the PARAGON trial demonstrated renal benefit in heart failure patients [14]. This further 
illustrated that approach to increase vasodilation that would lead to have a greater anti-
hypertensive effect is renoprotective in both diabetic and non-diabetic condition.  
1.2.2 Metabolic factors  
Brownlee in 2001 described how hyperglycemia leads to increased glycolysis generating excessive 
by-products that feed into four pathways; the polyol pathway, hexosamine pathway, production of 
AGEs, and activation of protein kinase C [15] . In the initial stage of glycolysis, glucose is broken 
down to 1,3 diphosphoglycerate by the enzyme glyceraldehyde-3-phosphate dehydrogenase 
(GADPH), which is a critical step as in the state of abundant glucose superoxide produced by 
electron transport chain that causes an upregulation of upstream components of glycolysis. The 
excess amount of glucose can be shunted through polyol pathway and reduced to fructose. This 
further cause decrease of glutathione resulting in increase of oxidative stress leading to increased 
cellular stress-mediated apoptosis. As the NADH:NAD+ ratio increases, it also increases the 
formation of methylglyoxalate and diacylglycerol, both of which are reported to be abundant in 
DKD patients ([16, 17]. It has been shown that in hyperglycemia, diacylglycerol (DAG) is 
chronically upregulated and contributes to sustained activation of protein kinase C (PKC), which 
contributes to DKD through several signaling pathways [18] . Activation of PKC can also 
contribute to the local hemodynamics by prostaglandin E2 and nitric oxide mediated vasodilation 
of afferent arterioles which then causes augmentation of angiotensin II-mediated vasoconstriction 
of efferent arterioles thereby contributing to glomerular hyperfiltration[19]. By products of 
increased activity of hexosamine pathway contribute to the increased renal cell hypertrophy and 
mesangial matrix accumulation that are the hallmark of DKD (34, 35 of Atta). Lastly irreversible 
glycation of proteins in presence of excessive glucose resulted in AGEs that is known to contribute 
to DKD in multiple ways. For example, AGEs have been shown to modify both laminin and type 
IV collagen thereby causing increased permeability of the glomerular basement membrane (GBM). 
In addition to that, increased concentrations of AGEs are known to dose-dependently increase 
density and expansion of the extracellular matrix activation by contributing to the increased 
expression of fibronectin and collagen types I and IV.   
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1.3 Structural changes in diabetic kidney disease 
One of the hallmarks of DKD is proteinuria, which occurs when the glomerular filtration barrier 
fails to retain the macromolecules, like albumin, within intravascular space. The glomerular 
filtration apparatus consists of three components-glomerular endothelial cells, visceral epithelial 
cells (podocytes), and glomerular basement membrane. It has been suggested that early changes 
in renal glomeruli are critical for the subsequent histopathological feature and nephron loss. 
Podocytes with their unique interdigitating foot processes are highly specialized terminally 
differentiated cells that sit on the glomerular basement membrane (GBM). In a normal healthy 
human the shape and integrity along with the charge barrier properties of the GBM is maintained 
by intricate network of glomerular endothelial cells and podocytes which are compromised in the 
diabetic glomerulus [1]. Chronic exposure to hyperglycemia induces ‘patho-adaptive’ progressive 
changes in podocytes, including cytoskeletal rearrangement, de‑differentiation, causing retraction 
and flattening (known as effacement) that ultimately detaches them from the slit diaphragm and 
eventually drop out [1]. Thickening of the GBM is regarded as one of the earliest and most 
characteristic of all glomerular changes in diabetes and can be seen via electron microscope within 
few years of diagnosis [20]. Under hyperglycemia, mesangial cells are also altered, undergoing 
proliferation and hypertophy thereby producing more matrix proteins leading to structural features 
of DKD. Diabetes-induced changes in the local environment resulted in recruitment of activated 
leukocytes, especially T cells and macrophages into the glomerulus and tubulointerstitium. 
Although this influx of inflammatory cells is due to tissue injury, the secreted cytokines, 
chemokines, activated complement and reactive oxygen species further mediate DKD [1]. In the 
early stage of diabetes, increased glucose load to the tubule induces maladaptive hypertrophy and 
hyperplasia that causes increased absorption of glucose and activation of the tubule-glomerular 
feedback that leads to increased hyperfiltration. The cumulative effect of the above changes is 
activated myofibroblasts, atypical collagen, inflammatory cells, and loss of capillary architecture 
that results in tubulointerstitial fibrosis [21]. These progressive changes in the different 
components of the kidney present a heterogeneous range of pathological features, that includes 
nodular or diffuse glomerulosclerosis, tubulointerstitial fibrosis, tubular atrophy and renal 
arteriolar hyalinosis, alone or in combination. 
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Figure 1.2. Pathological lesions of DKD. In normal human albumin is retained in the blood 
through an elaborate network of endothelial cells, basement membrane, podocytes, parietal 
epithelial cells that is called glomerular filtration barrier. In contrast, the diabetic glomerulus 
displays several histopathological features like arterial hyalinosis, mesangial expansion, 
collagen deposition, basement membrane thickening, podocyte loss and hypertrophy, that is 
clinically translated in high albuminuria, decreased glomerular filtration and ultimately lead to 
end stage renal failure.                                                                              Modified from Kimberly et 
al. 2014. 
1.4 Second messengers in chronic kidney disease 
Any systemic risk factors either hemodynamic or metabolic can act as ligands and bind to specific 
cellular receptors that alter protein confirmation to stimulate nearby effector proteins. These 
effectors can catalyze the production of molecules or in case of ions, increase the influx of ions 
that are called second messengers. They further diffuse rapidly to their targets elsewhere within 
the cell thus altering the activities as a response to the new information received by the receptors 
[22]. There are four classes of second messengers: cyclic nucleotides that signal within the cytosol; 
lipid messengers and ions like calcium that signal within and between cellular compartments and 
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gases and free radicals. Each of these second messengers can bind to specific protein targets, to 
modulate downstream signals by altering their activity. Given their importance in physiology, 
second messengers are tightly controlled to ensure precision in cellular signaling.  
1.4.1 Cyclic nucleotide signaling in kidney 
Cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP) are important intracellular second messengers that are involved in the 
transduction of a diverse array of physiologic stimuli. They play prominent roles in the 
development and progression of renal disease, including mitogenesis, inflammation, and fibrosis. 
A wide variety of G-coupled receptor mediated activation of adenylyl cyclase is responsible for 
generation of cAMP, whereas both receptor-associated and soluble guanylyl cyclase 
(sGCs)generates cGMP [23, 24]. Once produced they engaged the effector molecules to activate 
the downstream signaling pathways. For cAMP the effector molecule is predominantly cAMP-
dependent protein kinase A (PKA) and for cGMP it is protein kinase G (PKG). I addition to that  
cAMP-regulated guanine nucleotide exchange factors (cAMP-GEF, or EPACs), and cyclic 
nucleotide gated channels (9, 10) also act as effector molecules. Catabolism of cyclic nucleotides 
is always directed by phosphodiesterases (PDEs). The balance between synthesis and catabolism 
of cyclic nucleotides basically plays a pivotal role in regulating the amplitude, duration, and 
localization of cyclic nucleotide signaling. Preservation of cGMP either by activating the enzymes 
involved in the synthesis or inhibition of the enzyme that degrades them have been shown to have 
therapeutic benefits in kidney disease. Several lines of evidence suggested that both sGC 
stimulators or sGC activators increase intracellular level of cGMP and reduce kidney fibrosis in 
several different model of kidney fibrosis by inhibiting the TGFb pathway. For example clinically 
approved drug Riociguat, a sGC stimulator alone or in combination with an inhibitor of the  
angiotensin-II type 1 receptor (AT1R) improved renal function in a diabetic model of kidney 
disease by attenuating progression of renal fibrosis [25]. Moreover, in another rodent model where 
the disease was driven by volume and pressure overload it improved renal function by renal fibrotic 
tissue remodeling and reduced expression of several profibrotic markers [26].Cinaciguat, a sGC 
activator improved renal function by targeting sGC and increasing intracellular cGMP in a nephron 
loss model of CKD in rats [27]. Similarly, PDE5 inhibitors that specifically hydrolyze cGMP has 
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been shown to have renoprotective effects in multiple studies via their antiapoptotic and 
antioxidant properties. The PDE5 inhibitor sildenafil has been tested in both fibrosis and nephron 
loss model of kidney disease and shown improved renal function by increasing cGMP level and 
decreasing several key mediators of fibrosis pathway [28, 29]. Tadalafil was shown to prevent 
kidney dysfunction by preserving the renal structure and reducing several injury markers like 
KIM1 and NGAL in an ischemia-reperfusion injury model [30, 31]. Preservation of cAMP has 
been shown to have anti-fibrotic effect by blocking TGFb mediated gene transcription. The 
therapeutic options for enhancing cAMP are adenylate cyclase stimulators, PDE inhibitors, 
cyclosporine, or adrenomodulin; however, most of the data showing effect on kidney exist with 
PDE inhibitors. Roflumilast, a selective PDE4 inhibitor has shown renoprotective effect in 
streptozotocin-induced diabetic model of kidney disease by reversing pathology and attenuating 
apoptosis [32]. Pentoxifylline, a non-specific PDE inhibitor, has demonstrated renal benefits in 
various rodent model of kidney disease as well in clinical trial with type 2 diabetics and chronic 
kidney disease (CKD) by lowering the decline of estimated glomerular filtration rate in addition 
to RAS blockade [33]. Besides their direct effect as anti-fibrotic and anti-apoptotic cyclic 
nucleotides has been shown to induce vasorelaxation in the vascular system, which also can 
contribute to beneficial effects in the kidney by modulating the local and systemic hemodynamics. 
All of this evidence suggests that preservation of cyclic nucleotide has potential renal benefits. 
1.4.2 Cyclic nucleotide phosphodiesterase (PDE) and chronic kidney disease 
1.4.2 PDE family 
PDEs are a large family of enzymes that can hydrolyse cAMP and/or cGMP to their inactivated 
noncyclic nucleotides 5’-AMP and 5’GMP. They are the only cellular mechanism for degrading 
cAMP and cGMP, there by playing a major role in regulating the intracellular levels of these 
second messengers and, subsequently, modulating cellular activities. Based on their structure, 
primary sequence, substrate specificity and their pharmacological properties, PDEs are currently 
classified into eleven families. Majority of PDE families comprise more than one gene (~20 PDE 
genes), generating multiple protein products (> 50 PDE proteins) by alternative 5’ mRNA splicing 
[34]. The international nomenclature of PDE designated the gene families (types) of PDE by a 
capital letter to designate the product of a single PDE isogene also called “PDE subtype” and the 
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isoforms or variants are expressed by a numerical number. For example, for PDE1A1: gene family 
1 (type), gene A (subtype), and variant 1 (isoform). PDE family members have unique substrate 
specificity with PDE4, PDE7 and PDE8 hydrolyzing only cAMP, PDE5, PDE6, and PDE9 
hydrolyzing cGMP and PDE1, PDE2, PDE3, PDE10 and PDE11 hydrolyzing both [35].  
Despite differences, the different PDE isoforms share similar structural features. The catalytic 
domain of all mammalian PDEs is highly conserved, containing consensus sequences and motifs 
along with two consensus Zn binding sites. In addition, it also contains sequences specific to the 
family, determine the substrate affinities, and sensitivity to inhibitors. On the contrary the 
‘regulatory domain’ located in NH2-terminal vary widely among PDEs in structure and contain 
sequences targeted for different regulatory components. These include phosphorylation sites for 
different protein kinases like PKA or PKG, non-catalytic sites for cGMP and binding site for 
Ca2+/calmodulin . The small C-terminal domain of PDEs has recently been reported to have some 
MAPK dependent regulatory functions [23]. PDE family members largely differ in tissue 
distribution, inhibitor specificity and in mode of regulation. Although intracellular cyclic 
nucleotide concentration are major regulator but their activities can depend on the binding of 
Ca2+/CaM, phosphorylation, interaction with regulatory proteins or subcellular 
compartmentalization [35]. PDEs plays a vital role in balancing the concentration of cyclic 
nucleotides thereby modulating multiple signal transduction pathways to fine tune the 
physiological and pathophysiological processes that is now widely demonstrated in the literature 
such as erectile dysfunction, asthma, pulmonary hypertension, atherosclerosis, heart failure, and 
diabetes. Here we will review the role of PDEs in the context of renal disease with special emphasis 
on PDE1 as a potential therapeutic target for DKD. 
1.4.2.1 Role of PDEs in vascular contraction 
In 1970 Kukovetz and Poch first described the role of PDE in vascular contraction when they 
observed the vasodilator papaverine inhibits cAMP-PDE in vessel [36]. Since then, using specific 
PDE inhibitors several studies have reported the vasodilatory role of PDE1, PDE4 and PDE5 in 
isolated aorta from several species including human [37]. Using precontracted rat aorta with or 
without endothelium and specific PDE inhibitors it has been demonstrated that vasorelaxation 
induced by PDE3 is endothelium independent but PDE4 requires endothelium [38]. PDE4 has 
 
 
 
24 
 
been reported to be abundant in renal vasculature and Ro 20-1724, a PDE4 inhibitor has been 
shown to prevent endotoxin induced renal vascular resistance [39]. Moreover chronic infusion of 
the PDE4 inhibitor in zymosan-induced model of multiple organ dysfunction syndrome , a chronic 
inflammation induced organ failure model in mice, has shown to decrease mesenteric vascular 
resistance as well as improve renal function by preserving glomerular filtration rate and preserving 
cAMP [40]. PDE5, which is mainly present in vascular smooth muscle also participates in vascular 
contraction. Specifically, the PDE5 inhibitor, Zaprinast, mediates relaxation in rat and rabbit aorta 
in an endothelium-dependent manner [38, 41]. In kidney, PDE5 has been reported to express in 
vessel walls, glomeruli, mesangial cells, cortical tubules, and inner medullary collecting duct cells 
of rat kidney [42]. Several PDE5 inhibitors, like sildenafil and tadalafil, demonstrated renal benefit 
that is attributed to the vasodilatory feature of PDE5 inhibition. Sildenafil has demonstrated renal 
benefit in both a diabetic and non-diabetic pre-clinical model of CKD. In both mouse and rat model 
of diabetic nephropathy PDE5 inhibition by sildenafil showed improvement in renal function by 
reducing glomerular hyperfiltration. It also demonstrated renal benefit in a rat 5/6 uninephrectomy 
model by preventing glomerular hypertension and hyperfiltration [43]. This evidence clearly 
demonstrates that PDEs play an important role in maintaining the local vascular tone and thus 
exert its influence in controlling either local or systemic hemodynamics.  
1.4.2.2 Role of PDEs in inflammation and fibrosis 
Preservation of cyclic nucleotides by inhibiting PDEs has been shown to reduce inflammation and 
fibrosis is several diseases including renal disease. In rat mesangial using isoform-specific 
inhibitors, Chini et al demonstrated functional compartmentalization of intracellular pools of 
cAMP that are differentially regulated by PDEs [44]. They found that cAMP regulated by PDE3 
suppressed cell proliferation by inhibiting Ras-Raf MEK-ERK pathway whereas a PDE4-regulated 
cAMP pool suppresses cell inflammation by inhibiting MCP-1. Using both specific and 
nonspecific inhibitors, the role of PDEs in inflammation and fibrosis has been demonstrated in 
non-hemodynamic dependent models of CKD in animals. Roflumilast, a selective PDE4 inhibitor 
has shown antifibrotic and antiapoptotic capability in streptozotocin induced type-1 diabetic 
nephropathy [45]. PDE5 inhibitors sildenafil and tadalafil showed renal benefit in several different 
acute kidney injury model through their antiapoptotic and anti-fibrotic properties.  After treatment 
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with sildenafil for 14 days in acute unilateral ureter obstruction model, it reduced renal 
TGFb1/smad signaling along with mRNA expression of a-SMA, collagen type 1 and type III [28]. 
In a 5/6 renal ablation model sildenafil also improved renal function by reducing renal cell 
inflammation and apoptosis [46]. In both studies the renal improvement was associated with the 
preservation of cGMP. In a renal ischemia-reperfusion model, tadalafil has been shown to prevent 
renal damage as evidenced by decreased kidney injury marker (KIM-1) and neutrophil gelatinase-
associated lipocalin (NGAL), well-known kidney injury markers [45]. Besides these, 
pentoxifylline, a non-specific PDE inhibitor has been reported to ameliorate proteinuria by 
reducing interstitial inflammation and fibrosis in rat nephron loss model [35]. These evidences 
showed that apart from their effect on vascular contraction, PDEs also have other mechanism to 
influence the pathophysiology of renal disease. 
1.4.2.3 PDE1 and its potential role in renal biology 
Among all 11 PDEs, PDE1 is the only phosphodiesterase that is activated by a Ca2+/CaM-binding 
domain and has affinity for both cAMP and cGMP. The PDE1 family members consists of three 
isoforms that are encoded by three distinct genes, PDE1A, 1B, and 1C. Although dual substrate 
specific, PDE1A and PDE1B have higher affinity for cGMP than cAMP, whereas, PDE1C 
hydrolyses cGMP and cAMP with equal efficiency [47]. For PDE1A, at least seven splice-variants 
have been reported, among which PDE1A1 and PDE1A2 have been isolated from bovine heart 
and brain. PDE1B is particularly high in the striatum and so far only one gene product has been 
identified whereas five splice variants of PDE1C has been reported that localized in brain 
cerebellum, olfactory neurons, heart and testis [48]. All three isoforms, PDE1A, B and C are found 
to be expressed in pulmonary vasculature and aorta and mesenteric arteries in rats [49-51]. In rat 
cardiomyocytes and vascular smooth muscle cells, PDE1A was found to primarily regulate cGMP 
where as PDE1C regulates cAMP in aortic and pulmonary smooth muscle cells. PDE1C has been 
reported to be upregulated in the vasculature of rats with pulmonary hypertension whereas 
increased activity of PDE1A was found in rats with angiotensin II-induced systemic hypertension 
[49, 52]. Moreover, PDE1A has been linked to the development of hypertrophy and fibrosis in the 
hypertrophic rat heart [53]. All these evidences indicate PDE1 being a major player in regulating 
systemic hemodynamics. Several studies with specific and non-specific PDE1 inhibitors have 
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clearly showed improvement in vascular resistance and blood pressure both in vivo and ex vivo. 
Selective PDE1 inhibitors demonstrated blood pressure lowering effect in normal rats [52]. The 
role of PDE1C has been well characterized in the pathological cardiac remodeling and dysfunction. 
Using genetic and pharmacological approaches, Knight et al, demonstrated that inhibition of PDE1 
attenuated cardiac remodeling and dysfunction by antagonizing cardiac myocyte hypertrophy and 
death [54]. The non-hemodynamic properties of PDE1 has also been described in other tissue type 
including vascular smooth muscle. For example in rat aortic smooth muscle cells and in patient 
derived pulmonary arterial smooth muscle cells, genetic knock down or inhibiting the activity 
using a small molecule resulted in inhibition of cell proliferation and induced apoptosis [55, 56]. 
Expression of PDE1 isoforms have been reported to alter time of activation and differentiation of 
inflammatory cells which indicates PDE1’s potential role in inflammatory response. Indeed ITI-
214, a very potent PDE1 inhibitor has been shown to reduce LPS-induced increases in TNF-, IL-
1 and MCP-1 in microglia [57]. This is not surprising as being dual substrate specific, suppression 
of PDE1 can preserve cAMP which is a negative modulator of inflammatory cell responses 
including cytokine secretion and leukocyte as well increase availability of cGMP to attenuate LPS 
induced responses.  
 
In the kidney, PDE1A is expressed in the tubules, PDE1C is expressed in the glomeruli and tubules, 
and PDE1B is not expressed in either location [58]. Both the vasodilatory mechanism and anti-
inflammatory feature of PDE1 inhibition as seen in other tissue could potentially result in renal 
benefit. To date, no functional role of PDE1 has been reported in the kidney. Moreover, in diabetic 
nephropathy several risk factors like AngII, ET-1, and high glucose can increase intracellular 
calcium that might drive the upregulation of PDE1, thus implicating it to the pathophysiology of 
DKD.  
1.4.3 Intracellular calcium and kidney disease 
Calcium is an important intracellular messenger that engages in a wide range of cellular functions 
by direct binding to target proteins or stimulation of calcium sensors that then activate different 
downstream responses [59]. Either imported from the extracellular milieu or mobilized from 
intracellular stores it not only bridges extracellular and intracellular signal transduction as a second 
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messenger but also can regulate enzyme activity as a cofactor and modulate action potential [60]. 
Being so versatile in nature, intracellular calcium concentration is tightly controlled by an 
assortment of channels, pumps, transporters, buffers and effector moieties. Entry of calcium from 
external milieu is controlled by Ca2+ permeable channels such as transient receptor potential (TRP) 
and voltage gated Ca2+ channels. Calcium is also stored internally in different organelles like 
endoplasmic reticulum, Golgi, sarcoplasmic reticulum and acidic organelles of the endo-lysosomal 
system. Calcium has always been thought to related with the bone health but lately calcium 
homeostasis has been shown to be important in the regulation of insulin secretion from beta cells 
in the pancreas [61]. Increased intracellular calcium is thought to contribute to reduced β-cells 
function thereby promoting altered glucose homeostasis. In adipocytes and skeletal muscle, high 
cytosolic calcium has been inked to insulin resistance [62]. Moreover at least three studies have 
demonstrated that serum calcium level is higher in diabetic patients than non-diabetes [63-65]. The 
kidney plays an important role in maintaining the total body Ca2+ balance by filtering and 
reabsorbing calcium. Disruption in calcium signaling has been reported to result in kidney disease. 
The most relevant example is the evidence of gain and/or loss-of-function mutations in transient 
receptor potential canonical (TRPC) 6 (TRPC6) causing focal segmental glomerulosclerosis, 
which is manifested by severe albuminuria. Also mutation in polycistin 1/polycystin 2 genes has 
been linked to polycystic kidney disease and mutation is TRPM6 channels are found to be 
associated with hypomagnesemia, a condition that has been correlated with cardiovascular disease 
and all-causes of mortality in end-stage renal disease patients [66]. The discovery of these genetic 
mutations in calcium channels associated with hereditary kidney diseases signifies the importance 
of calcium signaling in the kidney disease although their role in DKD is not clear yet.  
1.4.3.1 Role of TRPC channel in kidney disease 
Podocyte health is crucial in maintaining the filtration capability of the kidney as it is key in 
regulating glomerular permeability. Elevation of intracellular calcium is regarded as one of the 
main pathological factors that drive the pathological changes in glomerular morphology and 
permeability. The transient receptor potential canonical (TRPC) channel belong to a superfamily 
called TRP channels that are non-selective cation channel with high Ca2+ permeability. They exist 
as tetramer with each subunit containing intracellular NH2 and COOH termini, six transmembrane 
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domains (S1–S6), and a pore loop between the S5 and S6 segments[67]. To date it is widely known 
TRPC channels are one of the major ion channel classes that regulate calcium influx inside the 
cell. Among seven structurally related family members, the importance of TRPC6 has been 
emphasized by the discovery of genetic mutation associated with focal segmental 
glomerulosclerosis (FSGS) which displays similar renal injury like loss of the glomerular filtration 
barrier cells and progressive albuminuria seen in DKD [68]. Studies have shown that 
overexpression of either wild type or any of the reported mutant version of TRPC6 in mice resulted 
in FSGS like disease [69]. Moreover, several studies have suggested that TRPC6 can be activated 
by molecules that are reported to be increased in disease conditions, especially in diabetes, and 
could potentially enhance calcium influx and trigger proteinuria. For example, one of the key 
mechanisms of TRPC6 activation involves DAG, that is generated by GPCR mediated stimulation 
of PLC [70]. Besides Gq mediated production, increased levels of glycolytic intermediates can 
also stimulate de novo synthesis of DAG. Many studies have shown that DAG levels are high in 
various tissues including glomeruli. Serum level of DAG has been reported to be elevated in 
diabetic patients [71]. Moreover, Gq receptors can be activated by multiple ligands: angiotensin 
II, Endothelin-1, thromboxane, prostaglandin E2 which are also reported to be elevated in diabetic 
condition [72-74]. Reactive oxygen species that is highly produced in diabetic conditions due to 
metabolic abnormality is another factor that has been reported to activate TRPC6. It has been 
demonstrated that ROS in particular hydrogen peroxide generated from NADPH oxidase is 
required for TRPC6 activation. In both podocyte and mesangial cells multiple studies have shown 
ROS mediated activation of TRPC6 resulted in injury of the cells [75]. In addition, TRPC6 
expression has been found to be elevated in various animal models of DKD. In streptozotocin 
induced rat model of diabetes in the background of both normal and hypertension, upregulation of 
TRPC6 was associated with high proteinuria and renal histopathology that is similar to human 
DKD [75, 76]. Wang et al using genetic approaches recently showed that TRPC6 KO resulted in 
attenuated tubule injury and reduced proteinuria until the later stages of the disease process in type 
1 Akita mice [77]. Although these data implicate TRPC6 as a major player in type-1 diabetic 
nephropathy, no data exist related to type-2 nephropathy.  
 
The downstream signaling pathway for TRPC6 has been extensively studied in podocyte and 
several signaling pathways has been linked to the phenotype related to glomerular disease. Several 
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authors have already demonstrated that activation of TRPC6 results in the apoptosis of podocyte 
via calcineurin-NFAT mediated signaling pathway [78, 79] without explaining the mechanism. It 
is well known that TRPC6 mediated calcium influx activate calcineurin-NFAT pathway whereby 
upon dephosphorylation NFAT goes into nucleus and activate a plethora of genes whose products 
can be other transcription factors, signaling proteins, secretory proteins, cell surface receptors, and 
other effector proteins any of which can be attributed to apoptosis. Multiple reports have indicated 
that NFAT mediated apoptosis might involve activation of intracellular signaling pathways or 
production of secreted proteins. The role of intracellular molecules in podocyte apoptosis as a 
result of calcineurin NFAT activation has been demonstrated by several authors [80, 81]. In those 
studies, they have identified NFAT dependent COX2 mediated ROS generation and an enhanced 
calcineurin/NFAT/Bax2 signaling pathway as one of the downstream effectors for podocyte 
apoptosis. It is fairly established that intracellular activation of COX2 or Bax/Bak signaling 
pathway leads to apoptosis but if TRPC6-mediated cell death involves either of these pathways is 
still unknown. In addition, activation of TRPC6 was shown to activate RhoA-Ras pathway and 
leads to cytoskeleton remodeling [66]. Given the number of calcium responsive proteins these 
mechanisms do not exclude the possibilities of other pathways that might be linked to similar 
disease phenotype.  
1.5 Use of computational biology in deciphering DKD 
Over the past several years tremendous progress has been made in understanding the 
pathophysiology of DKD, yet a clear mechanistic understanding is still lacking. The use of gene 
expression profiling has become a popular tool due to the availability of large amount of molecular, 
clinical and histopathological data from DKD patients. This created a new approach called system 
biology approach to understand DKD. In this approach using a set of experimental and 
computational tools, molecular changes are first identified in the whole kidney or more precisely 
in different interrelated kidney cells. Then these changes in cellular networks are then used to 
identify associations among the many molecular changes that might predict, enhance, or 
ameliorate disease progression in DKD patients. For the past several years, several authors 
reported either a new and novel mechanism or validated previously known mechanism using this 
approach. For example, Woroniecka et al. in their transcriptome analysis of human DKD, reported 
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vascular endothelial growth factor (VEGF) implicated in DKD, confirming the known biology, at 
the same time they also reported integrin pathway involved in the DKD pathogenesis [82]. They 
found that in both glomeruli and tubulointerstitium from DKD patients there is an increase in 
inflammation and fibrosis related gene expression. Data from other studies suggested that there is 
a cascade of activation of inflammatory genes with the progression of disease. For example in one 
study pathway mapping suggested that out of 138 known NF-kB responsive genes only one gene 
is enhanced in early disease where 54 are upregulated in progressive disease, thus emphasizing the 
progressive activation of inflammatory pathways in DKD [83]. Transcriptome analysis at tissue 
compartment level also helped deciphering mechanisms at tissue level. Transcriptomic analysis 
using glomeruli and tubulointerstitial tissues from patients with both early DKD and progressive 
DKD demonstrated differential activation of the JAK-STAT signaling pathway in glomeruli versus 
tubule. They reported that at early stage most of the JAK-STAT genes were expressed at 
substantially higher levels in the glomeruli; whereas, tubulointerstitial JAK-STAT gene expression 
was not elevated in early DKD but was higher in the patients with more progressive DKD [84]. 
One of the key limitations of all these studies is that they don’t point to a specific cellular 
phenotype. Moreover, with the availability of additional datasets, it would be interesting to 
delineate how much overlap exists in all of the data set to give a consensus sets of genes that are 
common is all DKD patients. Finding such consensus sets of genes and understanding their 
collective role in DKD pathogenesis might help to find a common mechanism.   
 
Although transcriptome analysis alone can help to have mechanistic understanding of the disease, 
sometimes alterations in a gene do not necessarily lead to proportionate changes in protein 
expression. In that case it becomes harder to link the molecular changes to a phenotype. Another 
approach of system biology might be to associate the molecular changes to cellular morphology 
or clinical phenotype. DKD is still confirmed by histopathological evaluation, thus emphasizing 
the role of structural changes as the hallmark of disease progression. The overarching goal of such 
approach would be to define the correlation of molecular changes to early-stage structural damage 
in DKD and their association with long-term outcomes. Using cortical interstitial fractional volume 
(VvInt), an index of tubule-interstitial damage and compartment-specific gene expression profiling 
from CKD patients Nair et al demonstrated the early molecular signature can be linked to the long-
term disease progression [85]. In a separate study, Beckerman et al. in an effort to identify key 
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driver modules in kidney expression data and correlate this with phenotypic outcomes found that 
molecular signature correlates well with structural changes rather than GFR [86]. These data 
demonstrate that relating transcriptomic data with histological features by corelating genotype to 
phenotype would provide better understanding of DKD pathogenesis rather than relying on only 
molecular data alone.  
1.6 Conclusion 
Despite the advancement of our understanding the mechanism of DKD, the available option for 
treating DKD is still to use an antagonist against ACE or ARB. Although with recent success of 
SGLT2 inhibitor and the observation of renal benefit of Glucagon like peptide 1 (GLP1) agonist 
and ET-1 antagonist might open up new therapeutic intervention; however, with ever increasing 
numbers of diabetic patients there is an urgent need for new therapeutic interventions. Preservation 
of cyclic nucleotides has been shown to be beneficial in renal disease [23, 43, 87]. Using multiple 
different preclinical renal disease models, several investigators have shown the beneficial role of 
cyclic nucleotides in the context of PDE4, that uses cAMP as substrate, and PDE5, that uses cGMP 
as substrate, by using class-specific inhibitors. In this context the question becomes, is preservation 
of both nucleotides beneficial for kidney? Moreover, the complex nature of DKD indicates that 
addressing multiple pathological changes such as alterations in hemodynamics or inflammation, 
concurrently, might offer greater benefits than focusing on a single pathology. From these 
perspectives PDE1 hypothetically fits nicely as its hemodynamics and anti-inflammatory features 
were shown by several investigators [39, 51, 52]. Moreover, according to the human protein atlas, 
PDE5 is not well expressed in glomeruli or tubule whereas PDE1 is highly expressed in both 
glomeruli and tubule thereby indicating its potential greater role in renal biology. Yet no single 
data exist exploring PDE1s role in renal biology. Among the 11 mammalian PDEs, PDE1 is the 
only PDE activated by calcium which is critical due to the calcium dysregulation observed in DKD 
patients. This fact also provide a strong rational to investigate the role of PDE1 in the context of 
diabetic renal disease as several of the risk factors in the diabetic milieu are known to activate ion 
channels, especially calcium channels. Yet no data exist about the relative abundance of calcium 
transporters in DKD patients. In cardiomyocytes it has been reported that TRPC3 associated 
calcium activates PDE1 and cause apoptosis. Similar mechanism has not been demonstrated in 
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any renal cell type [88]. The role of TRPC6 in FSGS has been clearly demonstrated and it is known 
to be present in all major type of renal cells. So, it would be interesting to see if TRPC6 is a major 
calcium channel associated with PDE1 activation. Finally, a severe limitation in finding a 
therapeutic intervention is a lack of animal models that recapitulate human CKD or DKD. Not 
only that animal models do not reflect the heterogeneity of human DKD but also often times the 
outcome measured in two species do not match. For example, in the search for agents to reduce 
fibrosis and progression of CKD, the efficacy readouts in animal would be multiple histological, 
histochemical and biochemical parameters, whereas in man the more restrictive end points would 
be mortality, glomerular filtration or proteinuria. One of the major reasons for failure in clinical 
trials is such kind of cross-species differences in translational research. Therefore, there is an 
urgent need to develop methodologies for reducing the gap between cross-species translational 
research. 
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 ROLE OF PHOSPHODIESTERASE 1 IN SYSTEMIC 
HEMODYNAMICS AND POTENTIAL IN DIABETIC KIDNEY DISEASE 
2.1 Introduction 
DKD is a major microvascular complication of diabetes that often results in either dialysis or 
kidney transplantation and poses a major global burden to healthcare. Approximately half of type-
2 and one-third of type-1 diabetic patients will develop DKD, which is clinically defined by the 
presence of impaired renal function as indicated by declining glomerular filtration or elevated 
urinary albumin excretion, or both [1]. Although the pathophysiology of DKD is multifactorial, 
the link with hemodynamic and metabolic factors is well established [10]. The initial driver for 
DKD is associated with a dysregulated metabolic milieu such as hyperglycemia, hyperlipidemia 
and insulin resistance. However, several clinical trials achieving metabolic benefits still failed to 
demonstrate improvement in renal disease, thus indicating involvement of other factors [2]. 
Hemodynamic factors like increased systemic blood pressure and intraglomerular pressure driven 
by the activation of several vasoactive hormone pathways like renin angiotensin system and 
endothelin-1 are also major contributors to the disease [89]. The current standard of care, ACE or 
ARB inhibitor and the recent successful SONAR trial [13] emphasized the role of hemodynamics 
in the pathophysiology of DKD. Moreover, the positive renal outcome seen in the CRDENCE trial 
with SGLT2 inhibition indicated that the renal benefit extends beyond the glycemic control and 
could be due to its effect in renal hemodynamic [90]. Despite the recent therapeutic advances there 
remains an unmet need for innovative treatment strategies to prevent, arrest, treat, and reverse 
DKD. Chronic metabolic and hemodynamic disturbances lead to the activation of several autocrine 
and paracrine factors that further cause structural changes in the kidney. Decades of research 
towards the understanding of the molecular mechanisms of DKD pathogenesis has made it possible 
to identify numerous new targets that open up opportunities for new therapeutic intervention.  
 
A major factor underlying kidney dysfunction involves defects of second messenger signaling, 
including cyclic nucleotides. Many renal functions, like solute transport and regulation of vascular 
tone has been shown to be modulated by cyclic nucleotides. Arginine-vasopressin mediates 
increases in cyclic adenosine monophosphate (cAMP) and atrial natriuretic factor induced cyclic 
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guanin monophosphate (cGMP) have been shown to be critical in the regulation of sodium and 
water retention [23]. The regulation of cyclic nucleotides in the cell is a balance between the 
synthesis of these molecules by adenylate cyclase and guanylate cyclase and catabolizing enzymes 
the cyclic 3´, 5´-nucleotide phosphodiesterases (PDEs) that play a pivotal role in regulating the 
amplitude, duration, and localization of cyclic nucleotide signaling.  In kidney, unique cellular and 
tissue distribution of PDEs contribute to cyclic nucleotide compartmentalization. Using PDE 
isoform specific inhibitors, several investigators have shown that PDEs exert different downstream 
effects by regulating the compartmentalization of cyclic nucleotides. For example, in mesangial 
cells, it has been demonstrated that although cAMP hydrolysis is directed by PDE3 and PDE4 but 
they play different function in terms of cellular physiology. Using using spatially restricted probes 
for cAMP, they have shown that the PDE3-regulated cAMP pool inhibits mitogenesis, whereas 
the PDE4-regulated cAMP pool regulates reactive oxygen species generation and monocyte 
chemoattractant protein-1 expression [91, 92]. Pharmacological intervention studies in pre-clinical 
models of both DKD and CKD have further demonstrated the functional role of several PDE 
isoforms in renal biology. Roflumilast, a selective PDE4 inhibitor, demonstrated renal benefits in 
streptozotocin induced type1 diabetic nephropathy.  Specifically, Roflumilast reduced oxidative 
stress, deposition of extracellular matrix proteins such as fibronectin and collagen, and inhibited 
apoptosis. PDE5 has been reported to be expressed in different parts of the kidney. In addition to 
tubule and glomeruli they also have been reported in inner medullary collecting duct cells, and 
mesangial cells. PDE5 inhibitors, including sildenafil and tadalafil, were renoprotective in pre-
clinical models of CKD and DKD through its vasodilatory, antiapoptotic and antioxidant 
properties [46]. This also translated in humans as PF-00489791, a long acting PDE5 inhibitor, 
reduced albuminuria in DKD patients [93]. In a small clinical trial of 90 type-2 diabetic patients,  
a selective inhibitor of PDE3, has proven to be effective in improving albuminuria and the 
expression of adhesion and pro-inflammatory molecules [94]. Although all isoforms of PDEs have 
been reported to be expressed in kidney [58] the functional role of other PDEs (beyond PDE 3, 4 
and 5) is still largely unknown. 
 
Among all 11 PDEs, PDE1 is the only phosphodiesterase that is activated by a Ca2+/calmodulin-
binding domain and has affinity for both cAMP and cGMP. All three isoforms, PDE1A, B and C 
are found to be expressed in pulmonary vasculature, aorta and mesenteric arteries in rats [49-51]. 
 
 
 
35 
 
PDE1A regulates cGMP in rat cardiomyocytes and vascular smooth muscle cells, whereas PDE1C 
regulates cAMP in aortic and pulmonary smooth muscle cells [52]. In vitro and ex vivo 
experiments have demonstrated the role of PDE1 in vasodilation. A selective pan-PDE1 inhibitor 
demonstrated blood pressure lowering effect in normal rats [52]. The role of PDE1C has been well 
characterized in pathological cardiac remodeling and dysfunction. Using genetic and 
pharmacological approaches, Knight et al, demonstrated that inhibition of PDE1 attenuated cardiac 
remodeling and dysfunction by antagonizing cardiac myocyte hypertrophy and death [54]. In the 
kidney, PDE1A is expressed in the tubules, PDE1C is expressed in the glomeruli and tubules, and 
PDE1B is not expressed in either location [58]. Both the vasodilatory mechanism and anti-
apoptotic feature of PDE1 inhibition could potentially confer renal benefit. As of yet, the 
functional role of PDE1 in the kidney has not been defined. Moreover, in diabetic nephropathy 
several risk factors like AngII, ET-1, high glucose can increase intracellular calcium that might 
drive the upregulation of PDE1. In mouse cardiomyocytes, calcium channel TRPC3 drove PDE1 
upregulation that lead to apoptosis of cardiomyocytes [95]. No such studies are known to exist in 
the context of renal biology. Therefore, we were prompted to investigate the role of PDE1 in 
kidney, especially in the context of diabetes. Herein, we describe a potent pan-PDE1 inhibitor and 
show in vivo its vasodilatory function using a novel method. Using the same pharmacological tool, 
we also demonstrate its beneficial role in diabetic kidney disease using a DKD model driven by 
diabetes, hypertension, and nephron loss. We demonstrate that the functional beneficial effect of 
PDE1 inhibition was associated with reduction of inflammation and fibrosis. We also demonstrate 
that PDE1 inhibition lead to lowering of blood pressure in both normal and hypertensive animals. 
Taken together, these observations strongly suggest potential therapeutic application of PDE1 
inhibition in DKD. 
2.2 Methods and materials 
2.2.1 Animals  
The animal care and experimental protocols in this study were conducted under the supervision of 
a veterinarian and in accordance with the Eli Lilly and Company’s Animal Care and Use 
 
 
 
36 
 
Committee. Whenever possible, procedures in this study are designed to avoid or minimize 
discomfort, distress, and pain to animals. Animals were purchased from the following vendors:  
Harlan (db/db KS with or without vendor-performed surgical removal of one kidney at 4–5 weeks 
of age), or Taconic (SD rats and SHR rats). Mice were fed ad libitum a standard 5008 diet (Lab 
Diets). Rats were fed with standard 2014 dies (Lab diets). Females were used in the obese type 2 
models to prevent risk of pyelonephritis. 
2.2.2 Generation of PDE proteins  
The nucleotide sequences encoding full-length human PDE1A (NP_001003683.1), PDE1C 
(NP_005011.1), PDE5A (NP_001074.2), PDE7B (NP_061818.1) and PDE9A (NP_002597.1) 
were inserted into pFastBac1 (Invitrogen) vector with an N-terminal HIS tag. The nucleotide 
sequences encoding full-length human PDE4D (NP_006194.2) and the catalytic domain (residue 
641-1141) of PDE3A (NP_000912.3) were inserted into pFastBac1 (Invitrogen) vector with a C-
terminal HIS tag. The nucleotide sequences encoding full-length human PDE8A (NP_002596.1) 
and PDE11A (AAI12394.1) were inserted into commercially available pFastBac1 (Invitrogen) 
vector with a Flag tag at N-terminal. The nucleotide sequences encoding full-length human 
PDE10A (AAD32595.1) were inserted into pFastBac1 (Invitrogen) vector with a C-terminal Flag-
His tag. The nucleotide sequences encoding full-length human PDE6A (NP_000431.2) and 
PDE6B (AAH00249.1) were inserted into pFastBacDua1 (Invitrogen) vector with an N-terminal 
HIS tag and N-terminal Flag tag, respectively, for production of PDE6A/6B dimer. Baculovirus 
generation and protein expression in Sf9 cells were carried out according to the protocol of Bac-
to-Bac Baculovirus Expression system (Invitrogen). The nucleotide sequences encoding full-
length human PDE1B (NP_000915.1) and PDE2A (NP_002590.1) were inserted into pIEX4 
(Novagen) with a C-terminal HIS tag, and both protein productions were carried out in Sf9 cells 
according to the vendor's protocol (Novagen). The HIS tagged PDE proteins were purified using 
Ni-NTA agarose (Qiagen) followed by size exclusion chromatography on a SUPERDEX® 200 
column (GE Healthcare) in storage buffer (20 mM Tris-HCl, pH7.5, 150 mM NaCl, 10% Glycerol). 
The Flag tagged PDE proteins including PDE6A/6B were purified using anti-Flag M2-agarose 
(Sigma), after purification through NiNTA column chromatography and eluted in storage buffer 
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(50 mM Tris-HCl, pH7.5, 150 mM NaCl, 10% Glycerol, 0.1 mg/ml Flag peptide). All purified 
proteins were stored at −80° C. in small aliquots. 
2.2.3 Phosphodiesterase enzyme assays  
All 3′, 5′ cyclic nucleotide phosphodiesterase (PDE) enzyme activities are measured with a 
radiometric enzyme assay based on SPA detection system (scintillation proximity assay). 
Compounds to be tested were diluted in pure dimethyl sulfoxide (DMSO) using ten-point 
concentration response curves. Maximal compound concentration in the reaction mixture was 
either 10 or 100 μM. Compounds at the appropriate concentration were pre-incubated with either 
of the PDE enzymes for 30 minutes before the reaction is started by the addition of substrate. 
Reactions are allowed to proceed for 60 minutes at room temperature. Next, reactions were stopped 
by addition of SPA beads. Samples were read 12 hours later in a MICROBETA™ TRILUX® 
Counter. “IC50” refers to the concentration of the compound that produces 50% of the maximal 
inhibitory response possible for that compound. IC50 values are calculated by plotting the 
normalized data vs. log [compound] and fitting the data using a four-parameter logistic equation. 
2.2.4 IC50 calculation 
For each test compound, % Inhibition is calculated using the equation below: 
% Inhibition= 100 - [((Test Compound – Median Min)/(Median Max - Median Min)) x 100] 
where the signals are defined as: 
Test Compound = signal for test compound 
Min = signal in the absence of agonist 
Max = signal in the presence of agonist  
% Inhibition (Y-axis) is plotted against log concentration of test compound (X-axis) and analyzed 
using a 4-parameter nonlinear logistic equation (ABase Equation 205) as shown below: 
y = (A+((B-A)/(1+((C/x)^D)))) where, y = % specific inhibition A = Bottom of the curve, B = Top 
of the curve, C = Relative IC50 = concentration causing 50% inhibition based on the range of the 
data from top to bottom and D = Hill Slope = slope of the curve. 
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2.2.5  Calcium-calmodulin dependent PDE enzyme assays  
PDE1A, PDE1B, and PDE1C were cloned and purified in house following standard protein 
generation procedures. The assay buffer is prepared to give a final concentration of 50 mM Tris-
HCl, 50 mM MgCl2, 4 mM CaCl2, 0.1% Bovine serum albumin and 6 U/ml Calmodulin in water, 
at pH 7.5. The final enzyme concentration is 0.25, 0.074 and 0.0012 nM, for PDE1A, PDE1B, and 
PDE1C, respectively. The reactions were started by addition of the substrate, [3H]cAMP, at a final 
concentration of 47 nM. 
2.2.6 PDE enzyme assays using [3H]cAMP as substrate 
The following phosphodiesterase activities were measured using [3H]cAMP as reaction substrate: 
PDE3A (catalytic domain), PDE4D, PDE7B and PDE8A. All these enzymes were cloned and 
purified in house following standard procedures. The assay buffer is prepared to give a final 
concentration in the assay of 50 mM Tris-HCl, 8.3 mM MgCl2, 1.7 mM 
ethylenediaminetetraacetic acid (EDTA) and 0.1% Bovine serum albumin at pH 7.5. Final enzyme 
concentrations are 0.008, 0.021, 0.5 and 0.06 nM for PDE3A, PDE4D, PDE7B and PDE8A 
respectively. Reactions are also started by addition of the substrate, [3H]cAMP, to give a final 
concentration of 47 nM. 
2.2.7 PDE enzyme assays using [3H]cGMP as substrate 
The following phosphodiesterase activities are measured using [3H]cGMP as reaction substrate: 
PDE2A, PDE5A, PDE6A/6B, PDE9A, PDE10A and PDE11A. The catalytic active form of PDE6 
is a dimer composed of a (PDE6A) and b subunits (PDE6B). The dimer of PDE6A/6B is produced 
by the expression and purification strategy, using two purification steps, i.e., NiNTA and anti-
FLAG Sepharose chromatography. The rest of the enzymes are cloned and purified in house 
following standard procedures. The assay buffer is prepared to give a final concentration in the 
assay of 50 mM Tris-HCl, 8.3 mM MgCl2, 1.7 mM EDTA and 0.1% Bovine serum albumin at pH 
7.5. Final enzyme concentrations are 0.2, 0.002, 5, 1, 0.03 and 0.03 nM for PDE2A, PDE5A, 
PDE6AB, PDE9A, PDEI0A and PDE11A, respectively. The reactions are started by addition of 
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the substrate, [3H]cGMP, to give a final concentration of 80 nM in the case of PDE2A, PDE10A, 
PDE5A, PDE6AB and PDE11A assays, whereas for PDE9A 20 nM of [3 H]cGMP is used. 
2.2.8 ReninAAV db/db uNx model for renal failure 
In vivo assessment of  DKD Progression in ReninAAV and corresponding control LacZAAV were  
obtained as previously described [96]. In brief, Mice received a single retro-orbital injection of 
ReninAAV (5 X 1010 GC per animal) or LacZAAV at approximately 12 weeks of age. Body 
weight, blood glucose levels, and proteinuria were measured after 4wks to evaluate the disease 
progression. Once the disease establishment was confirmed by their albuminuria mice were 
randomized based on the above parameters. Mice were treated with either vehicle or PDE1 
inhibitor for 6wks. Urine was collected bi-weekly. At the end of the study mice were euthanized, 
and the half of the remaining kidney was collected and fixed in 10% neutral buffered formalin for 
histologic processing and the remaining half was snap frozen for RNA processing. Serum and 
plasma were collected at necropsy for measurement of serum creatinine (enzymatic creatinine 
using a protocol validated by HPLC).  
2.2.9 Rat telemetry studies 
Male Sprague Dawley rats, Spontaneous Hypertensive rats (Charles River Laboratories, USA), 
implanted with Data Science International transmitters (HD S10) for collection of blood pressure 
(BP) and heart rate (HR) data in aseptic conditions. The transmitters that was implanted in animals 
by the vendor, are capable of transmitting a signal via a pressure catheter inserted into the 
abdominal aorta. Baseline was established and recorded. After they were randomized based on 
their baseline hemodynamic parameters each rat was then removed from its recording cage and 
was dosed twice a day by p.o. gavage with vehicle or compound, and the animals were then 
returned to the recording cage. Data sampling for blood pressure and heart rate was carried out in 
intervals at selected time points for 24hours. 
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2.2.10 Rat Ear temperature 
Male Sprague Dawley rats were purchased from Taconic Biosciences at 6 to 7 weeks of age. They 
were dosed orally by p.o. gavage with different doses of LY1, the pan PDE1 inhibitor was 
formulated in 1% hydroxyethlycellulose (Dow Corning, Midland, MI) (w/v), 0.25%  
Table 1: Body weight, proteinuria and blood glucose level of the dbdb renin AAV mice 
Group 
 
Proteinuria 
(mg/g) 
 Body 
weight 
(g) 
Blood 
glucose 
(mg/dl) 
DbDb Renin AAV-Vehicle 10716.25 39.2 253.5 
DbDb Renin AAV-Vehicle 32678.57 44 247 
DbDb Renin AAV-Vehicle 32821.92 52.9 358 
DbDb Renin AAV-Vehicle 33757.01 51.8 447.5 
DbDb Renin AAV-Vehicle 42547.17 53.02 510 
DbDb Renin AAV-Vehicle 43229.17 41.6 253 
DbDb Renin AAV-Vehicle 45375 50.1 255.5 
DbDb Renin AAV-Vehicle 50075.95 44.8 202 
DbDb Renin AAV-Vehicle 53720.93 50.4 311 
DbDb Renin AAV-Vehicle 66126.44 57.2 313.5 
DbDb Renin AAV-LY1-0.3mg/kg 10071.43 58.3 273 
DbDb Renin AAV-LY1-0.3mg/kg 17784.72 43.3 449 
DbDb Renin AAV-LY1-0.3mg/kg 27176.8 43.3 231.5 
DbDb Renin AAV-LY1-0.3mg/kg 28806.72 50.2 274 
DbDb Renin AAV-LY1-0.3mg/kg 35355.56 49.7 425 
DbDb Renin AAV-LY1-0.3mg/kg 43985.4 46.5 287.5 
DbDb Renin AAV-LY1-0.3mg/kg 48818.79 49.1 172 
DbDb Renin AAV-LY1-0.3mg/kg 49508.77 54.6 505 
DbDb Renin AAV-LY1-0.3mg/kg 54395.06 42.4 271.5 
DbDb Renin AAV-LY1-0.3mg/kg 61094.49 49.2 183.5 
DbDb Renin AAV-LY1-1 mg/kg 12891.72 44 127.5 
DbDb Renin AAV-LY1-1 mg/kg 15862.07 46.7 281 
DbDb Renin AAV-LY1-1 mg/kg 26285.71 56.3 239.5 
 
 
 
41 
 
Group 
 
Proteinuria 
(mg/g) 
 Body 
weight 
(g) 
Blood 
glucose 
(mg/dl) 
DbDb Renin AAV-LY1-1 mg/kg 34142.86 49.9 294.5 
DbDb Renin AAV-LY1-1 mg/kg 41811.76 54.5 260 
DbDb Renin AAV-LY1-1 mg/kg 43359.55 42.4 489.5 
DbDb Renin AAV-LY1-1 mg/kg 45276.6 49.8 207.5 
DbDb Renin AAV-LY1-1 mg/kg 54216.56 45.6 531.5 
DbDb Renin AAV-LY1-1 mg/kg 68552.63 43.1 480.5 
DbDb Renin AAV-LY1-1 mg/kg 71627.27 48.4 272.5 
DbDb LacZ 1464.84 48.9 246 
DbDb LacZ 3136.45 48.6 316 
DbDb LacZ 2071.25 59.6 585 
DbDb LacZ 3734.26 58.3 295.5 
DbDb LacZ 883.95 52 120 
DbDb LacZ 2234.18 47.6 261.5 
 
polysorbate 80 (Sigma-Aldrich, St. Louis, MO) (v/v), and 0.05% antifoam (v/v; Dow Corning, 
Midland, MI) in purified water. Following dosing, ear temperature was measured by using a k-
type thermocouple probe digital thermometer every hour for 6 hrs and then at 24 hrs. Blood 
samples for plasma exposure measurement were obtained at the same time. Blood was collected 
via a tail snip directly into a 20-μL EDTA-coated capillary and immediately spotted onto a 
Whatman DMPK-C DBS card (GE Healthcare Bio-Sciences, Piscataway, NJ). Tail snips were 
performed by removing approximately 1 mm of the tail by using a scalpel. Blood flow was initiated 
by gentle squeezing of the tail. No analgesia or anesthesia was used during blood collections. A 
single sample and spot were collected per time point. The DBS cards were allowed to dry for 
approximately 2 h at room temperature, after which the cards were placed in a zip-top bag, stored, 
and shipped at ambient temperature. 
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2.2.11 Histopathologic Evaluation 
The histopathological evaluation of the kidneys were done as described previously [97]. Kidneys 
fixed in 10% formalin were transversely trimmed, processed, paraffin embedded, microtome 
sectioned at a thickness of 5mm. They were then stained with either hematoxylin and eosin, or 
Masson trichrome, or periodic acid–Schiff. After required incubation and washing steps as per the 
protocol tissue sections were examined by light microscopy. A board certified veterinary 
pathologist assigned scores for several histopathological parameters like tubular regeneration, 
tubular protein, tubular dilation, and interstitial inflammation. Glomerular injury, expansion of the 
mesangium, and integrity of tubular basement membranes were evaluated based on the Periodic 
acid–Schiff-stain in similar manner. Masson trichrome–stained slides were evaluated for 
interstitial and glomerular fibrosis. A score from zero to five (normal to severe, respectively) was 
used to describe the histological changes in compound treated group compared with controls. 
Following are the description of the individual scores: 
no changes or changes consistent with spontaneous background finding in the age, sex,      
and/or strain; minimal (score one) 
0%–10% affected; slight (score two):  
10%–25% affected; moderate (score three):  
25%–50% affected; marked (score four):  
50%–75% affected; and severe (score five) 
2.2.12 Isolation of rat glomeruli 
Before the experiment, a fresh solution of RPMI1640 with 5% bovine serum albumin (BSA) was 
made and referred to as solution A. SD rat was euthanized using CO2 followed by a secondary 
method of killing. After perfusion using a needle through the ventricle, the kidneys were removed 
and de-capsulated. Pelvis and medulla were removed as much as possible along with the perirenal 
adipose tissue . Kidney was cut in half sagittal with a single edged razor and place it in a petri plate 
on ice. The cortex was isolated using a curved scissor. It was finely minced with razor blade in a 
small amount of PBS in the petri plate and rinse pieces onto #140 sieves presoaked in solution A 
(only the area to be used was soaked to minimize the use of solution A) resting on a collection pan 
using the PBS from the wash bottle. The pieces were gently pushed through sieve mesh using 
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circular motion with the spatula. The underside of #140 sieve was rinsed with the wash bottle and 
allowed to drain briefly into a pan. A #80 sieve was placed on top of #200 sieve in sink, holding 
both at a 450 angle. The suspension was poured over sieves, using only the lower 1/3 of the total 
area. The collecting pans were rinsed with 100 ml aliquots of PBS 2-3 times, pouring over sieves. 
Finally, the glomeruli were collected with the BSA coated pipette tip and transferred to a 50 ml 
conical flask. They were centrifuged at 600-100RPM for 5 minutes, and PBS was carefully 
aspirated off. The glomeruli were re-suspended in appropriate volume of PBS and used for 
subsequent experiments.  
2.2.13 Enzyme-Linked Immunosorbent Assay (ELISA) 
Direct ELISA was performed to detect urinary NGAL, Kim-1, MCP-1 and GDF-15 using 
commercial kits and following their direction. Briefly, urine samples were thawed approximately 
1 h before the assays were performed. For all measurements, 100 μL of diluted urine sample was 
analyzed in duplicate. For quantification, an 8-point standard curve was prepared by a 1:3 dilution 
of a premixed standard containing all analytes of a specific panel. The recommended dilution of 
500-fold was optimal for the detection of NGAL and KIM-1, whereas no dilution was required for 
the detection of Kim-1 and GDF-15. Urinary antigens were bound to the wells of microtiter plates 
by incubation of 100 μL urine samples for 1 h at 37°C. Wells were blocked with buffer containing 
5% BSA. The primary antibody was mouse monoclonal against mouse NGAL (MLCN20; 
Quantikine ELISA, R&D Systems), mouse Kim-1 (MKM100; Quantikine ELISA, R&S Systems), 
mouse MCP-1 (MJE00; Quantikine ELISA, R&S Systems) and mouse GDF 15 (MGD150; 
Quantikine ELISA, R&S Systems). Incubation was followed by treatment with horseradish 
peroxidase-conjugate was added for color development. 30 minutes later the reaction was stopped 
by adding 100ul of HCl. The plate was then read at 450 nm with a Benchmark Plus microplate 
reader (Bio-Rad, CA, USA). The urinary creatinine (Cr) concentration was used to normalize all 
analyte measurements to account for the influence of urinary dilution on its concentration. Urinary 
levels of biomarkers were expressed as analytes/Cr ratio in ng/mg creatinine.  
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2.2.14 Urinary cAMP and cGMP measurement in rats 
To evaluate the acute effect of PDE1 inhibition on urinary cyclic nucleotides male Sprague Dawley 
rats were dosed with either vehicle or PDE1 inhibitor and a 24-hr urine was collected by placing 
them in metabolic cage. Urinary cAMP and cGMP were measured using the respective ELISA kit 
(for cAMP kit cat#501040, for cGMP cat# 501040) from Caymen chemicals following their 
instruction. Briefly urine samples were thawed approximately 1 h before the assays were 
performed. For all measurements, 100 μL of diluted (1:500) urine sample was analyzed in 
duplicate. For quantification, an 8-point standard curve was prepared by a 1:2 dilution of a 
premixed standard. The urinary Cr concentration was used to normalize all analyte measurements 
to account for the influence of urinary dilution on its concentration.  
2.2.15 Measurement of apoptosis using Caspase-3/7 Green Detection Reagent 
Cellular apoptosis was detected by using CellEvent™ Caspase-3/7 Green ReadyProbes™ Reagent 
from Thermo-Fisher Scientific (cat# R37111). For the human mesangial cells about 20K cells per 
well were plated in 96-well black walled plate. The next day, cells were treated with hyperforin 9 
at different doses along with DMSO and incubated for 4 hrs at 370C. A solution of CellEvent™ 
3/7 caspase dye was made by adding 2 drops/ml of PBS. Hoechst stain solution was made by 
adding 2.5ul of 2mg/ml solution in 10ml PBS. Thirty minutes before the 4-hr incubation period 
ended, both dyes were added in total of 200 ul volume. After 30 minutes of incubation, cells were 
fixed with 4% paraformaldehyde. For rat glomeruli isolation, about 80 glomeruli per well were 
plated in 96 well black walled plate. They were incubated in RPMI 16 medium with 10% fetal 
bovine serum (FBS) overnight. Next they were treated with hyperforin 9 and incubated for 24 hrs. 
In case of compound treatment, isolated glomeruli were pre-incubated for 1 hr. Before measuring 
the signal, the glomeruli were incubated with both caspase and nuclear dye for 30 minutes. Images 
were captured using a high throughput imaging Arrayscan VTI and analyzed with the Target 
Activation BioApplication using two channels at a magnification of ×10. An algorithm was used 
to identify objects by nuclear staining with Hoescht dye at 365nm, and caspase signal was captured 
at 475 nm wavelength. All fluorescent intensities are displayed as relative fluorescent units. 
 
 
 
 
 
45 
 
2.3 Results 
2.3.1 Effect of LY1 on PDE1 activity 
Using a radiometric enzyme assay based on scintillation proximity assay (SPA) detection system 
LY1 was tested against all recombinant PDE enzymes. LY1 inhibited all three isoforms of PDE1 
with very comparable half maximal inhibitory concentrations (IC50) (1.74nm, 2.44nm and 1.20nm 
for PDE1A, PDE1B and PDE1C, respectively) (Fig. 2.1), while other PDEs were only affected at 
μM concentrations (Table 2).  
2.3.2 Development of rat model of vasodilation   
We used ear temperature measurement to examine if PDE1 inhibition would cause vasodilation in 
the rats’ ear. The hypothesis behind the ear temperature method was the assumption that PDE1 
inhibition-induced vasodilation would increase the blood flow in the rat ear that would 
subsequently increase the surface temperature. Sprague Dawley rats were administered orally a 
single dose of LY1 at 0.03, 0.1, 0.3, 1 or 3 mg/kg and ear temperature was measured every hour 
for up to 6 hrs and then finally at 24 hrs. Indeed, there was a significant rapid increase of ear 
temperature, 14% at the highest dose of 3 mg/kg within 1 hr of dosing compare to the vehicle 
control as shown in figure 2.2A. Also, a significant dose-dependent increase in ear temperature 
was observed at 0.1, 0.3 and 1 mg/kg.  The calculated ED50 was 0.14 mg/kg (Fig. 2.2B). The 
response in ear temperature sustained for almost 3 hrs in all groups except the lower dose groups 
and returned to baseline by 6 hrs. The pharmacokinetic analysis of LY1 correlated with the 
observed change in ear temperature and calculated the half-life as 4 hrs (Fig. 2.2D). The calculated 
percent target engagement based on the unbound drug concentration demonstrated about 65% 
target engagement (TE) at the lowest dose at 1hr and saturated after 0.3mg/kg (Table 2).  
2.3.3 LY1 lowered blood pressure in normal and spontaneously hypertensive rats 
Vasodilation is an integral part of the regulation of systemic hemodynamics. In general, any 
dilation of arteries and arterioles leads to an prompt decrease in arterial blood pressure. To evaluate 
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Figure 2.1. Inhibition of PDE1 enzyme activity by LY1. LY1 was pre-incubated with 
different recombinant PDE1 isoforms for 30 minutes before the addition of the substrate. After 
incubating at room temperature for 60 minutes reactions were stopped by addition of SPA beads. 
cAMP levels were measured after 12 hrs. “IC50” refers to the concentration of the compound 
that produces 50% of the maximal inhibitory response possible for that compound. IC50 values 
of A) PDE1A, B) PDE1B and C) PDE1C were calculated by plotting the normalized data vs. 
log [compound] and fitting the data using a four-parameter logistic equation. 
 
. 
 
 
 
 
 
 
 
Table 2: Inhibition of PDE enzyme activity by LY1 
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Figure 2.2. Effect of LY1 on ear temperature in rats. Sprague Dawley rats were orally dosed 
with 0.03, 0.1, 0.3, 1 or 3mg/kg of LY1 and the temperature of the pinnae measured with a K-
probe thermometer at every hour for up to 6 hrs and then at 24 hrs after dosing. A) Ear 
temperature was plotted against time, B) an ED50 of 0.14 was calculated at the 1hr time point. 
Data are given as mean ± SEM (N=5). C) One-way ANOVA analysis demonstrating significant 
change in ear temperature in rats with PDE inhibition. Data represents mean of group average 
with N=5 and the p-value calculated compared to the vehicle group. D. Pharmacokinetic profile 
of LY1. Plasma concentrations of LY1 were determined after a single oral administration of 
0.03, 0.1,0.3, 1 and 3 mg/kg of the compound to male Sprague Dawley rats. Data are given as 
mean ± SEM (N=5).  
 
the blood pressure lowering effect of PDE1 inhibition in normotensive animals, LY1 was 
administered in freely moving telemetered Sprague Dawley (SD) rats. Rats were dosed at 1 and 3 
mg/kg twice daily via oral gavage, and data were captured every hour for 24 hrs. Figure 2.3 
demonstrates a rapid reduction in blood pressure that was sustained for several hours. A decrease 
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Figure 2.3. Effect of LY1 on the hemodynamics of SD rats. Telemeterized SD rats were 
dosed twice daily and A) diastolic blood pressure, B) mean arterial pressure, C) systolic blood 
pressure and D) heart rate were recorded for 24 hrs. Dotted line represents the timing of doses. 
All the data represented here as SEM.  
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Figure 2.4. Effect of LY1 on the hemodynamics of SHR rats. Telemeterized SHR rats were 
dosed twice daily and A) diastolic blood pressure, B) mean arterial pressure, C) systolic blood 
pressure and D) heart rate were recorded for 24hrs. Dotted line represents the timing of doses. 
All the data represented here as SEM.  
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of about 5 mm Hg was observed in both groups within 1hr of the first dose compared to the vehicle. 
In general, the blood pressure lowering effect was sustained for longer in high dose group and 
returned to baseline 7hrs after the second dose. A dose-dependent increase in heart rate was also 
observed that returned to baseline towards the end of the time of recording. The blood pressure 
lowering effect of PDE1 inhibition as observed in normal rats suggested that this might be 
beneficial in the context of hypertension. In order to test this, telemetered genetically spontaneous 
hypertensive rats (SHR) that exhibit spontaneous hypertension were dosed twice orally with either 
LY1 at 0.03, 0.1, 0.3, 1 and 3 mg/kg or a vehicle, and cardiovascular parameters were recorded for 
24 hrs. As shown in Figure 2.4, a dose-dependent decrease in blood pressure was observed along 
with increase in heart rate. Within the first hour of dosing, an acute decrease of about 30 mmHg 
was observed in 1 and 3mg/kg dose groups compared to only 5 mmHg drop in normal SD rats at 
the same dose level. A dose dependent increase in heart rate was also evident in SHRs with 
relatively greater magnitude compare to SD rats at the same dose level. The lowest dose of 
0.03mg/kg did not show any effect in both BP and heart rate.  
 
The magnitude of blood pressure lowering effect was much greater in SHRs than in normal rats 
when compared at the same dose level. ACE inhibitors are used as standard of care for the clinical 
management of hypertensive patients. In order to evaluate the additive effect of PDE1 inhibitor 
with ACE inhibitor, SHRs were orally dosed twice a day with either 3 mg/kg enalapril alone or in 
combination with 0.3 mg/kg of PDE1 inhibitor, and cardiovascular parameters were recorded for 
24 hrs. As expected, enalapril lowered the mean arterial pressure by 15% without affecting the 
heart rate (Fig. 2.5). The co-administration of LY1 with enalapril, an ACE inhibitor lowered mean 
arterial pressure by almost 20% with significant increase in heart rate which sustained for almost 
5hrs but came down to baseline.   
2.3.4 LY1 attenuated disease progression in the mouse model of DKD 
To determine the role of PDE1 in the pathogenesis of DKD we used a mouse model of severe 
diabetic nephropathy. Following unilateral nephrectomy at 4-5 weeks old, dbdb mice were injected 
with AAV virus carrying a renin gene at 12-13 weeks of age. The combination of unilateral 
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Figure 2.5. Effect of LY1 on the hemodynamics of SHR rats on top of enalapril. 
Telemeterized SHR rats were dosed twice daily and A) diastolic blood pressure, B) mean arterial 
pressure, C) systolic blood pressure and D) heart rate were recorded for 24hrs. All the data 
represented here as SEM. 
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nephrectomy and induction of renin-mediated hypertension resulted in about 18-fold increase in 
albuminuria compare to the AAV-lacZ control animals. Following randomization based on 
albuminuria, body weight and blood glucose level, the animals were administered either LY1 twice 
a day orally at 0.3 or 1 mg/kg for 6 wks or vehicle. Dosing with the PDE1 inhibitor led to 
significant dose dependent decrease of albuminuria that was evident as early as 14 days and 
sustained for 6 weeks of treatment (Fig 2.6A). LY1 treated group showed a reduction in urine ACR 
of about 51% and 69% at 0.3mg/kg and 1mg/kg group, respectively, compared to vehicle after 6 
weeks of treatment. Interestingly, in the 1 mg/kg dose group LY1 not only attenuated disease 
progression but also significantly reduced albuminuria (by 45%) when compared to the pre-dose 
albuminuria which suggests a possible restoration of kidney function beyond the baseline. The 
reduction of albuminuria was significant at each time point collected for both doses except in low 
dose group at the 6-week time point. We also measured serum creatinine to evaluate kidney 
function. As expected, the AAV renin mice demonstrated an almost two-fold increase in serum 
creatinine compare to the AAV-lacZ treated animals. Treatment with LY1 for 6 weeks reduced 
serum creatinine significantly compares to the vehicle treated group (Fig 2.6B). The lower dose 
group did not show any change in serum creatinine. Administration of AAV renin increased heart 
weight significantly compared to the lacZ group which was dose dependently decreased with LY1 
treatment which indicates a potential cardiovascular benefit. There was no significant change in 
kidney weight in observed across all groups. (Fig. 2.6C). 
2.3.5 LY1 improved histopathology in DKD mouse model 
Renal histopathology was evaluated in db/db UNIX-AAV-Renin mice treated with 0, 0.3, and 1 
mg/kg of LY1. As reported earlier [97], overexpression of renin in uninephrectomized  db/db 
induced severe pathological changes compared to the AAV-lacZ mice. The vehicle-treated group 
demonstrated significantly increased deposition of mesangial matrix, intraglomerular fibrosis, 
periglomerular fibrosis/inflammation, and dilated kidney tubules. Though renal morphologic 
variability existed within and between treatment groups, mice treated with 1 mg/kg of LY1had 
less severe kidney changes when compared to untreated AAV-Renin mice. The changes observed 
included significantly fewer dilated tubules with proteinaceous filtrate, less glomerular matrix, 
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decreased glomerular and peri-glomerular fibrosis and sclerosis, and less renal inflammation (Fig 
2.7).   
 
 
Figure 2.6. Effect of PDE1 inhibition in DKD. Four weeks after the induction of renin-
dependent hypertension in the unilateral nephrectomy model in db/db mice, they were treated 
twice with either vehicle or two different doses of LY1 for 6 weeks. Treatment with the PDE1 
inhibitor markedly decreased A) albuminuria and B) serum creatinine compare to the vehicle 
group. Mice treated with the PDE1 inhibitor showed reduced C) heart weight and D) kidney 
weight after normalized with brain weight. All the data represented here as mean±SD, with 
N=10 in each group. 
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2.3.6 LY1 reduced fibrotic and inflammatory gene expression 
Histopathological evaluation of the study indicated increased fibrosis and inflammation in the 
dbdb AAV renin model which improved upon PDE1 inhibition. To further identify relevant gene 
expression profile associated with the improvement in histopathology, microarray analysis of gene 
expression was performed using the mRNA isolated from the kidney. The preliminary gene chip 
data demonstrated a change in the set of genes involved in inflammation, fibrosis and innate 
immunity signaling pathways in LY1 treated animals compared to control but did not reach 
significance. The list of genes modulated were further followed up with RT PCR using low density 
gene expression array card. Several fold increase in some key inflammatory genes were seen in 
the vehicle control group compare to LacZ group, thereby confirming increased inflammatory 
response in the disease model (Fig 2.8A). PDE1 inhibition significantly attenuated the 
inflammatory response (almost to the baseline) at 1mg/kg dose. Similarly, there was a several fold 
increase in fibrotic gene expression in the control group which were attenuated by PDE1 inhibition. 
Ingenuity pathway analysis (IPA) revealed that the top three canonical pathways associated with 
the total number of genes downregulated upon PDE1 inhibition. As expected, one of the pathways 
was associated with acute phase response. Interestingly a number of affected genes was associated 
with Liver X receptor/Farnesoid X receptor activation and prothrombin activation pathway. A 
number of genes that were downregulated by PDE1 inhibition are reported to be associated with 
renal inflammation, renal tubule injury and kidney failure (Fig 2.8B). 
2.3.7 LY1 reduced urinary bio markers of kidney injury 
Having seen such a significant improvement in the renal pathology and corroborating changes in 
the gene signature in the LY1 treated animals, we explored several non-invasive biomarkers 
indicative of kidney injury. Several urinary biomarkers like NGAL, KIM1, MCP1 and GDF15 
were measured via ELISA to evaluate the effect of PDE1 inhibition in this preclinical model of 
DKD. The urinary neutrophil gelatinase-associated lipocalin (NGAL), which is widely regarded 
as a marker for renal tubular damage progressively increased in the AAV renin treated animals 
compare to the lacz control. Urine collected at a 2 week time point demonstrated a 5-fold increase 
in urinary NGAL in the AAV renin treated animals compare to lacz animals, which progressively 
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Figure 2.7. Histopathological changes in renin AAV db.db AAV uNx mice upon 
inhibition of PDE1. A) Representative images of kidney sections stained with H&E , Masson 
Trichrome (MTS) and periodic acid-Schiff (PAS) from mice treated with either vehicle or 
LY1 for 6wks. Renin AAV db/db uNx mice treated with LY1 showed reduction in glomerular 
matrix, decreased glomerular and peri-glomerular fibrosis and sclerosis, and less renal 
inflammation compared to vehicle treated group. B) Quantification of pathological changes. 
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Figure 2.8. Gene expression analysis of fibrotic and inflammatory markers. Taqman 
analysis using Gene expression array card showing changes in the inflammatory and fibrotic 
genes in AAVrenin db/db mice compare to lacZ and LY1 treatment reduced the expression of 
those gene. A) volcano plot B) List of genes that are changed in inflammation and fibrosis 
pathway.  
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increased and showed a 17-fold increase at 6 weeks. PDE1 inhibition by LY1 significantly 
attenuated the elevation of urinary NGAL as early as within 2 weeks and maintained it for 4 weeks 
in dose-independent manner (Fig 2.9).  
 
Kidney Injury Marker (KIM-1) is a well validated marker for acute kidney injury. Urinary KIM-1 
was highly elevated in a 2-week urine sample in the AAV renin treated group compare to the lacz 
animals which demonstrated significant kidney injury in this model. The elevation in KIM1 was 
progressive and reached as high as 18-fold elevation in the diseased animal in 6 weeks. PDE1 
inhibition by LY1 significantly attenuated the progressive elevation of urinary KIM1 as early as 2 
weeks and maintained it for 2 weeks. At 6 weeks, the high dose group still showed significant 
reduction in KIM-1 although the low dose group lost the significance. Reduction of urinary KIM-
1 was significantly associated with albuminuria (R2= 0.78, p val <0.0001) after 6wks of treatment 
with PDE1 inhibitor (Fig 2.10).  
 
Monocyte chemoattractant protein 1 (MCP-1) belongs to a group of inflammatory chemokines 
which is reported to be elevated in DKD. In the vehicle treated AAV renin mice, there was a 
massive increase (about 64-fold) in urinary MCP-1 compare to the lacz control as early as 2 weeks. 
MCP-1 progressively increased during the study. Inhibition of PDE1 by LY1 attenuated the 
increase of MCP-1 as early as within 2 weeks after dosing, and that was maintained during the 
study. At 6wks, reduction of MCP-1 was found to be associated with ACR (R2=0.78, p val <0.0001) 
(Fig 2.11). Interestingly, neither KIM-1 nor MCP-1 showed any significant change in the blood, 
although KIM-1 showed a trend in treated animals compare to the vehicle group (fig 10 and 11). 
Urinary growth differentiating factor 15 (GDF-15) has been found to be increased about 4-fold 
within 2weeks and progressively increased up to 7-fold in 6wks in diseased animals compare to 
the lacZ. Inhibition of PDE1 significantly reduced the level of GDF15 within 4-6 weeks (Fig 2.12) 
which also correlates with albuminuria.  
2.3.8 Acute effect of LY1 on cyclic nucleotides in the rat urine 
In order to explore the effect of PDE1 inhibition on the urinary cyclic nucleotides, normal SD rats 
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Figure 2.9. Urinary level of NGAL is decreased in AV renin db/db uNx mice following 
PDE1 inhibition. Mice were treated with 0 (vehicle), 0.3 or 1mg/kg of LY1 for 6wks. Biweekly 
urine was collected and urinary NGAL was measured using commercially available ELISA kit. 
Vehicle treated AAVrenin db/db mice showed significant increase in uNGAL which is reduced 
significantly upon treatment with LY1. 
 
 
Figure 2.10. Urinary level of KIM-1 is decreased in AAV renin db/db uNx mice following 
PDE1 inhibition. Mice were treated with 0 (vehicle), 0.3 or 1mg/kg of LSN3191567 for 6wks. 
Biweekly urine was collected and urinary KIM-1 was measured using commercially available 
ELISA kit. Blood was collected at the end of the study and KIM-1 was measured in the serum 
using ELISA. A) Vehicle treated AAVrenin db/db mice showed significant increase in KIM-1 
which is reduced significantly upon treatment with LSN3191567. B) Serum KIM-1 showed a 
trend but did not rech significane. C) Scatter plot showing correlation between urinary KIM-1 
and proteinuria (r2=0.77, p<0.001) at 6wks. 
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were orally dosed twice daily with LY1 either at 0.3 or 3mg/kg and urine was collected for 24 hrs 
using metabolic cage. A significant increase in the urine volume was observed in both dose groups 
that corroborated reduction in urinary creatinine (fig 13). This increase in urine volume 
demonstrates a potential diuretic effect of PDE1 inhibition. For the cyclic nucleotide levels, a trend 
of increasing cAMP level in the urine has been observed which did not reach significance. 
However, a significant increase in cGMP has been observed in LY1 treated rats compare to the 
vehicle group (Fig 2.13). 
2.3.9 Expression analysis of major calcium channels in patients with CKD 
Thus, we have demonstrated that PDE1 inhibition provided significant therapeutic benefits in the 
animal model of DKD. On the flipside, it means that PDE1 activity is critical for disease 
pathogenesis. PDE1 is activated by calcium-calmodulin. However, the source of calcium for PDE1 
activation in this context is unknown. To narrow down the list of calcium channels that are 
important in kidney disease we first did a literature search and found about 11 channels so far 
reported to contribute in calcium signaling in the kidney. Majority of the channels falls into the 
category of transient receptor potential canonical channel (TRPC) and voltage-gated channels. The 
channels that are found to play a role in several cellular function in kidney by modulating calcium 
signaling are TRPC1, TRPC3, TRPC5 TRPC6, TRPV4, TRPV5, PKD1/PKD2, Voltage gated 
channels Cav3.1, v3.2, v1.2 and v2.1. To further rank them based on their differential expression 
in different compartments of the kidney, we analyzed their gene expression in CKD patients 
database. Differential expression analysis of these 11 genes were done using the ERCB patient 
dataset which contained microarray data of micro dissected kidney biopsy samples from 199 CKD 
patients. In the tubular compartment, we found no change in the expression of the 11 channels (Fig 
2.14). On the other hand, the glomerular gene expression data revealed that TRPC6 is the most 
upregulated gene among 11 channels in all five different CKD types including DKD (Fig 2.14). 
This data signifies the importance of TRPC6 as major channel that is involved in the kidney disease 
pathophysiology. 
2.3.10 LY1 attenuated renal cell apoptosis induced by in vitro activation of TRPC6 
To investigate whether TRPC6 mediated activation of PDE1 plays a direct role in renal cell 
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Figure 2.11. Urinary level of MCP-1 is decreased in AAV renin db/db uNx mice following 
PDE1 inhibition. Mice were treated with 0 (vehicle), 0.3 0r 1mg/kg of LY1 for 6wks. Biweekly 
urine was collected and urinary KIM-1 was measured using commercially available ELISA kit. 
Blood was collected at the end of the study and KIM-1 was measured in the serum using ELISA. 
A) Vehicle treated AAVrenin db/db mice showed significant increase in KIM-1 which is 
reduced significantly upon treatment with LY1. B) Serum KIM-1 showed a trend but did not 
rech significance. C) Scatter plot showing correlation between uKIM-1 and proteinuria 
(r2=0.78, p<0.001) at 6wks. 
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Figure 2.12. Urinary level of GDF15 is decreased in AAV renin db/db uNx mice following 
PDE1 inhibition. Mice were treated with 0 (vehicle), 0.3 0r 1mg/kg of LY1 for 6wks. Biweekly 
urine was collected and urinary GDF15 was measured using commercially available ELISA kit. 
A) Vehicle treated AAV renin db/db mice showed significant increase in GDF15 which was 
reduced significantly upon treatment with LY1. B) Scatter plot showing correlation between 
GDF15 and proteinuria (r2=0.66, p<0.001) at 6wks. 
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Figure 2.13. Effect of PDE1 inhibition on urinary cyclic nucleotide in normal rats. Sprague 
Dawley rats were dosed with either 0.3 or 3 mg/kg of LY1. Rats were kept in metabolic cage 
following first dose and urine were collected for 24hrs. Urinary cyclic nucleotides were 
measured using ELISA. A) LSN3191567 treated animals showed a significant increase in cGMP 
but a trend in increase in cAMP. B) Dose dependent increase in urine volume upon LY1 with 
concomitant decrease in urinary creatinine. 
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Figure 2.14. Gene expression analysis of the calcium channels in the microdissected kidney 
samples of CKD patients in ERCB cohort. Bar chart showing the A) glomerular and B) tubular 
gene expression of calcium channels in CKD patients. 
 
apoptosis, we used TRPC6-specific activator in primary human mesangial cell and measured 
cleaved caspase 3/7 activity as a marker of apoptosis. Primary human mesangial cells were treated 
with different doses of hyperforin 9 or in some cases they were pre-treated with small molecule of 
TRPC6 or PDE1 inhibitor for 1hr and then treated with hyperforin 9 for 6hrs. Cellular apoptosis 
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Figure 2.15. Effect of PDE1 inhibition on TRPC6 mediated apoptosis in human mesangial 
cell. Primary human mesangial cells were treated with different doses of hyperforin 9 for 24hrs. 
In other experiments hMS cells were pre-incubated with either small molecule of TRPC or PDE1 
inhibitor for 1hr and then treated with 25uM hyperforin 9 for 6hrs. A) Confocal microscopic 
imaging of caspase 3/7 activity in cells at 10X magnification. B) Quantitative representation of 
the caspase activity. All data was represented as standard error of mean. 
 
was measured by caspase 3/7 activity as detected using high throughput imaging platform using 
caspase 3/7 specific dye.  
 
Hyperforin 9 treatment induced significant apoptosis in dose-dependent manner in mesangial cell, 
which can be blocked by TRPC6 inhibitor (Fig 2.15). In addition, PDE1 inhibition also attenuated 
hyperforin 9 induced apoptosis thereby positioning PDE1 as a downstream mediator of TRPC6 
induced apoptosis.  
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Next, we wanted to investigate this phenomenon in more complex cellular system using isolated 
rat glomeruli. Our preliminary data demonstrated that the level of apoptosis could depend on the 
number of glomeruli per well. Therefore, first, we decided to optimize the glomeruli number that 
is enough for our study without any spontaneous apoptosis. After isolating the rat glomeruli using 
the method described in the material and methods section, different numbers of rat isolated 
glomeruli were plated on a 96-well plate. They were incubated for 24 hrs, and the next day caspase 
activity was measured using the same technique. We found that a high number of glomeruli was 
Figure 2.16. Effect of glomerular number on apoptosis. 96 well plate was seeded with 
different number of glomeruli and incubated in the media for 24hrs. Following 24hrs incubation 
caspase activity was measured using Cell Evet caspase 3/7 green dye. Confocal microscopic 
images taken at 4X showing the optimum number of glomeruli that did not induce any apoptosis. 
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indeed associated with spontaneous apoptosis, and a count of 94 glomeruli per well is the optimum 
number for plating (Fig 2.16).  
 
As described earlier, 96-well plate was plated with the optimum number of isolated rat glomeruli 
and treated with different dose of hyperforin 9 or in some cases they were pre-treated with either 
PDE1 or TRPC6 inhibitor for 1 hr and then treated with 100 µM of hyperforin 9 for 24hrs. Cellular 
apoptosis was measured by caspase 3/7 activity. Hyperforin 9 dose dependently significantly 
induced caspase activity which can be attenuated by TRPC6 inhibitor or PDE1 inhibitor in dose 
dependent manner (Fig 2.17). 
 
Figure 2.17. Effect of PDE1 inhibition on TRPC6 mediated apoptosis in isolated rat 
glomeruli. Rat isolated glomeruli were treated with different doses of hyperforin 9 for 24hrs. In 
other experiments rat glomeruli were pre-incubated with either small molecule of TRPC or 
PDE1 inhibitor for 1hr and then treated with 100uM hyperforin 9 for 24hrs. A) Confocal 
microscopic imaging of cleaved caspase 3/7 activity in rat glomeruli at 4X . B) Quantitative 
representation of the caspase activity. All data was represented as standard error of mean. 
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2.4 Discussion 
In this chapter, using a novel technique, for the first time we demonstrated evidence of PDE1 
dependent vasodilation in vivo using a small molecule inhibitor. We also have demonstrated its 
blood pressure lowering effect in both normal and spontaneously hypertensive rats and 
demonstrated additive effect to the standard of care treatment. We also used the same 
pharmacological approaches in vivo to explore the role of PDE1 in DKD and shown that inhibition 
of PDE1 improved renal function in an animal model of DKD that closely resembles human DKD. 
The renal benefit was manifested by significant reduction in proteinuria, improved glomerular 
filtration rate along with improved histopathological features compare to the vehicle treated 
animals. Molecular and urinary biomarker analysis revealed the renal benefit might be exerted by 
inhibition of inflammation and fibrosis. To the best of our knowledge, this is the first time 
demonstration of the role of PDE1 in DKD. Using both in vitro and ex vivo technique, we further 
demonstrated that calcium channel is the likely source of calcium responsible for activation of 
renal PDE1. TRPC6 mediated activation of PDE1 caused renal cell apoptosis. Overall, these data 
indicate that PDE1 may be a potential player in the progression of diabetic kidney disease, and 
inhibition of this phosphodiesterase presents a potential therapeutic opportunity. 
2.4.1 Hemodynamic effects of PDE1 inhibition 
PDE1 attracted interest in the context of arterial hypertension when, in human genetics study, an 
association of PDE1A single nucleotide polymorphism with diastolic and mean blood pressure 
was described [98]. At a fundamental level, the study of hemodynamics is concerned with the 
distribution of pressures and flows in the circulatory system. In its simplest form, the flow of blood 
through the blood vessel depends on the pressure exerted by heart and the peripheral resistance. In 
other words, to increase blood flow, one could either increase the cardiac force or decrease the 
systemic vascular resistance [99, 100]. The vascular resistance largely depends on the size and the 
shape of the blood vessels which is maintained by the contraction of the vascular wall mediated 
by the contraction of smooth muscle cell. 
 
Cyclic nucleotides are ubiquitous second messengers that are known to play an important role in 
regulating vascular tone. PDE1 is expressed in smooth muscle cell (SMC) and can lead to 
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degradation of both cAMP and cGMP [47]. All three isoforms, PDE1A, B and C are found to be 
expressed in pulmonary vasculature, aorta and mesenteric arteries in rats [49, 56, 101]. PDE1A 
has been shown to regulate cGMP in rat cardiomyocytes and vascular smooth muscle cells [102], 
whereas PDE1C was shown to regulate cAMP in aortic [103] and pulmonary smooth muscle cells 
[56]. Lately Khammy et al. using in situ hybridization demonstrated that relative expression of 
PDE1A in VSMC of the vascular wall of rat mesenteric arteries is higher than the other two 
isoforms [51]. Giachini et al, showed that arteries from Ang II-infused hypertensive rats, display 
increased PDE1 expression and activation compared to control rats, and pharmacological 
inhibition of PDE1 abolished differences in the contractile responsiveness between the groups [49]. 
Recently Laursen et al showed selective inhibition of PDE1 induced relaxation in mesenteric as 
well as in femoral arteries from rats [52]. 
 
Although these ex-vivo studies demonstrated vasodilatory role of PDE1, in vivo demonstration of 
vasodilation relies on invasive techniques or sophisticated methods using ultrasound or imaging 
under anesthesia. For example, Cheng et. Al. has shown the niacin induced vasodilation in mouse 
using a laser doppler imaging technique [104]. Regardless, no such data exist showing in vivo 
vasodilation for PDE1. Here, for the first time, we demonstrated in vivo vasodilatory effects of a 
novel selective PDE1 inhibitor using very simple and reproducible method. The idea of using ear 
temperature as a surrogate for vasodilation came from the observation during dosing of LY1 in 
rats for an unrelated study. We observed the rapid reddening of the rat ear followed by concurrent 
warming of the rat ear after the dosing of the compound. As we measured the temperature using a 
thermometer equipped with k-probe thermocouple, indeed we saw about 12% increase in rat pinna 
temperature in the highest dose of LY1 treated animals compare to vehicle group. We also have 
demonstrated a dose dependent increase in ear temperature and the phenomenon repeated in other 
active compounds (data not shown). The pharmacokinetic analysis demonstrated sufficient 
exposure of the compound with a projected half-life of about 4hrs. It also revealed that we obtained 
about 64% target engagement with the minimum dose of 0.03mpk and saturated the target at 
0.3mpk. The PK/PD analysis shown that the linear relationship between change in ear temperature 
and corresponding target engagement ratio remained linear for one hour.  
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The phenomenon of cutaneous relaxation or hot flushing is associated with many drugs, like PDE5 
inhibitor [105], niacin [106], selective serotonin reuptake inhibitors (SSRIs), and few others [107]. 
In all cases patients have demonstrated redness or warmth of the face, neck or chest area. Although 
differ in initial stimulus, in general all these treatments lead to the same phenotypic response, i.e. 
‘hot flushing’ associated with vasodilation. Intuitively, we associated the increase in temperature 
with this phenotypic response and went ahead to measure the temperature of rat pinna as the hot 
flush was remarkably evident in that area. Thus, the ear temperature has been used as surrogate 
marker of vasodilation. However, relationships between compound exposure and ear temperature 
are more complex. While at the early time points after the dosing ear temperature directly 
correlated with compound plasma concentration, the effect on ear temperature started to disappear 
at 3hr whereas the half-life of the compound is almost 4hrs. One explanation could be the 
homeostatic mechanism involved in the control of body temperature. LY1 at high dose 
demonstrated about 12-14% increase in ear temperature. In case of such increase in body 
temperature some negative feedback mechanism, independent of vasodilatory effect of PDE1 
inhibition, might play a role in bringing down the temperature. It is well recognized that changes 
in skin blood flow played an important role in maintaining core body temperature within a very 
narrow range [108]. One such mechanism involves arterio-venous anastomoses (AVA) [109] 
which in human are abundant in finger and toes. Hoyer et al suggested its importance in 
temperature regulation in mammals.  It has been shown that with the rise in body temperature 
induced AVA dilation to distribute the heat throughout the body [110]. Usually, this regulatory 
feedback acts instantly but the fact that rat ear don’t have AVA but tail does might explain the 
delay in response [111]. Due to this reason and the fact that the linear relationship between change 
in temperature and target engagement ratio (TER) stayed only for an hour, the ear temperature 
might be a useful surrogate for vasodilation within that time frame. Taken together, LY1, a potent 
and selective PDE1 inhibitor with appropriate pharmacokinetic properties demonstrated 
vasodilation using a novel noninvasive method.  
 
When blood vessels dilates, decrease in vascular resistance results in increase of blood flow  [112]. 
Therefore, dilation of small arteries and arterioles leads to an instantaneous decrease in arterial 
blood pressure [113]. Several non-selective PDE1 inhibitors like IBMX, SCH51866, zaprinast or 
vinpocetine have shown blood pressure lowering effect in both normal or AngII infused rats [102, 
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114, 115]. The lack of specificity in those molecules makes it harder to implicate PDE1s role in 
hemodynamics. For example, vinpocetine has also been shown to inhibit PDE7B in micro molar 
range [116]. Furthermore, vinpocetine directly inhibits BKCa channels [117], and recently 
vinpocetine was found to have a PDE independent mechanism to inhibit NF-kB dependent 
inflammation [118]. However, very recently selective PDE1 inhibitor has been shown to reduce 
blood pressure in rats [52]. In our study we also have seen a dose dependent decrease in mean 
arterial pressure in normal rats that coincides with an increase in heart rate. We also demonstrated 
similar phenomenon in spontaneously hypertensive rats, a genetic model of hypertension. The 
magnitude of blood pressure lowering effect is higher in SHR rats and can be achieved with much 
lower dose compare to normal animals. ACE inhibitors are regarded as standard of care in the 
clinic for hypertensive patients. Our data clearly demonstrated a significant synergistic effect in 
lowering blood pressure when combined with LY1. Interestingly while enalapril did not increase 
the heart rate, the combination raised the heart rate to an extent that is higher than seen with 
compound alone in SHR animal.  
 
PDE1 is likely to be involved in multiple mechanisms regulating blood pressure. Our data strongly 
suggest that peripheral vasodilation could play critical role. Literature data suggested relaxation of 
pre-constricted aortic rings with both specific and non-specific PDE1 inhibitors [52, 119].  Our in 
vivo findings complement these in vitro observations. We  have shown that LY1 increased rat ear 
temperature in a dose-dependent manner. This change is temperature is likely a result of increased 
local blood flow driven by vasodilation. Importantly, plasma levels of the compound and, hence, 
tissue exposure, were comparable with compound concentrations in vitro that induced vasodilation 
and exceeded IC50 for PDE1A. Given that diameter of small arteries and arterioles is directly 
related to peripheral vascular resistance, and the latter, together with the pumping capacity of the 
heart and blood volume, ultimately defines blood pressure, we surmise that vasodilation could be 
the main mechanism of antihypertensive effects of PDE1 inhibitors.  
 
Since PDE1A is the major isoform expressed in arterial smooth muscle cells [49, 51], it is highly 
likely that blood pressure lowering activity of LY1 is primarily driven by its inhibition of PDE1A. 
Preferred substrate of PDE1A is cGMP that is produced in vascular smooth muscle cells (SMC) 
by nitric oxide-induced soluble guanylate cyclase or natriuretic peptide-activated particulate 
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guanylate cyclase [34]. Downstream, cGMP signaling is associated with activation of protein 
kinase G, ultimately leading to smooth muscle cell relaxation. When PDE1 is activated, it degrades 
cGMP and hence impedes vasorelaxation. PDE1 is the only phosphodiesterase activated by 
calcium [120]. Calcium signaling is enhanced in arterial hypertension [121]. Therefore, it is 
reasonable to suggest that PDE1A activation serves as one of the major mechanisms associated 
with increased peripheral vascular resistance, and its inhibition would have significant therapeutic 
benefit. 
 
PDE1 inhibition, however, could also be responsible for an observed increase in heart rate. 
Tachycardia is not unique to LY1. It is likely to be the class effect since structurally unrelated 
PDE1 inhibitors increased heart rate in different species of experimental animals [122]. Precise 
mechanism of PDE1-induced tachycardia needs to be further investigated. However, it likely has 
both extracardiac and intracardiac components. The former could be a result of baroreflex, an 
activation of sympathetic signaling induced by blood pressure lowering [123] that, to some degree, 
is germane to any peripheral vasodilator [124]. The latter is likely to be specifically associated 
with inhibition of PDE1A. Lukyanenko et al. reported that PDE1 is expressed in the rabbit 
sinoatrial node. While cGMP is a preferred substrate of this enzyme, PDE1 is also capable of 
binding to (albeit with lower affinity) and degrading cAMP. cAMP, in turn, can stimulate calcium 
signaling resulting in increased pacemaker activity [119]. It is still unknown whether this 
mechanism is involved in tachycardia in the rat, and, most critically, is translatable to the human. 
ITI-214, a PDE1 inhibitor with similar potency and selectivity, has finished Phase II clinical trial 
for Parkinson’s disease (ClinicalTrials.gov Identifier: NCT03257046). Although no data related 
to heart rate were published, the very fact that this compound is moved to Phase II is indicative of 
an overall beneficial safety profile. Thus, tachycardia could remain primarily pre-clinical finding. 
However, more detailed translational studies are needed. 
 
In general, cross-species translation remains an issue given significant difference in the patterns of 
PDE1 expression in the heart. Recent paper by Hashimoto et al [122] demonstrated that PDE1 
inhibition in the dog was simultaneously associated with positive inotropic effects (most likely 
driven by inhibition of PDE1C in cardiomyocytes) and peripheral vasodilation (most likely driven 
by inhibition of PDE1A in vascular SMCs). This “ino-dilation” provides intriguing prospects for 
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PDE1 inhibitors which could pave the way for new therapeutic approach in hypertension or related 
disease like chronic kidney disease.  
 
Association of vascular resistance with CKD is well established. In participants of the US National 
Health and Nutrient examination Suvery (NHANES), hypertension in women was strikingly 
associated with decline of kidney function [125]. Later  Varaniemi K et al demonstrated that there 
is an independent association between systemic vascular resistance induced hypertension and 
lower eGFR [126]. Having seen the vasodilatory effect in both ex vivo and in vivo along with 
lowering of blood pressure we wanted to investigate the role of PDE1 in the context of CKD. 
Among different types of CKD, the prevalence of DKD constitutes about more than 50% and in 
both type 1 and 2 diabetic patients intracellular calcium has been reported to be higher than 
normal[127]. 
2.4.2 Renal benefits of PDE1 inhibition in diabetic nephropathy 
To recapitulate human diabetic nephropathy and explore the role of PDE1 we used an animal 
model that has combination of hypertension and nephron loss on the background of type 2 diabetes. 
In this severe mouse model of diabetic nephropathy, we demonstrated that small molecule PDE1 
inhibitor attenuates the progression of diabetic nephropathy as indicated by reduction in 
albuminuria, serum creatinine, and several urinary biomarkers like NGAL, KIM1, MCP-1 and 
GDF-15. We also demonstrated marked reduction in glomerular sclerosis, interstitial fibrosis, and 
mesangial matrix accumulation in the PDE1 inhibitor treated group compare to the vehicle. Gene 
expression analysis demonstrated that PDE1 inhibition also attenuated the upregulation of several 
genes related to inflammation and fibrosis. Taken together, these data provide first pre-clinical 
demonstration of renal benefit of PDE1 inhibitor in the context of diabetic kidney disease.  
The biology of PDE1 has been investigated in heart and brain extensively but, to the best of our 
knowledge, no data exist describing its role in diabetic kidney disease.  According to human 
protein atlas data, PDE1A is largely expressed in tubules, and PDE1C is expressed in both tubules 
and glomeruli, while PDE1B is not expressed in the kidney. Although nothing is known about the 
primary role of PDE1 in the context of DKD, it certainly can influence several components of the 
disease pathophysiology. For example, the course of disease in DKD can be influenced by local 
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hemodynamics. One major factor regulating hemodynamics is over activation of renin angiotensin 
system (RAS). Activation of the RAS leads to increased angiotensin II levels which subsequently 
cause efferent arteriolar vasoconstriction thus increasing intra glomerular pressure[18]. Increased 
levels of angiotensin II are associated with high albuminuria and nephropathy in both humans and 
mice [128, 129]. This is further validated by a long track record of ACEIs and ARBs in reducing 
the doubling rate of creatinine, albuminuria, and progression to nephropathy, ESRD, and death 
both in human and animal [130-133]. The vasodilatory and blood pressure lowering effect of PDE1 
inhibition led us to explore the role of PDE1 in the context of diabetic nephropathy. 
 
The animal model used in this study is characterized by severe albuminuria, increased serum 
creatinine and histopathological changes that are very similar to human DKD[97]. In this model, 
hypertension is induced by the AAV mediated overexpression of renin, and renal insufficiency is 
induced by unilateral nephrectomy on the background of type 2 diabetes. We demonstrated that 
treatment with PDE1 inhibitor significantly and dose dependently decreased albuminuria within 
two weeks of dosing, and this beneficial effect persisted for 6 wks. This was accompanied by the 
significant reduction in serum creatinine in the high dose group after chronic treatment. The 
improvement in albuminuria in the early phase of the treatment might be due to the modulation of 
glomerular hemodynamics exerted by the vasodilatory mechanism of PDE1 inhibition.  
 
Persistent albuminuria is one of the salient features of DKD and is clinically recognized as a marker 
of the severity of chronic kidney disease. Recent study showed that patients with higher 
albuminuria are prone to cardiovascular death even in some cases where they were in range that 
was otherwise known as at ’normal’ albumin excretion range [134]. Reduction in albuminuria in 
both diabetic and non-diabetic patients with renal disease translates into a protection from renal 
function decline [135, 136] Like albuminuria, serum creatinine is also a well-established 
biomarker of any renal disease. Traditionally, eGFR is used to characterize kidney function and to 
determine the stage of kidney disease.  
 
Chronic exposure to hyperglycemia and hemodynamic changes that modulates various 
intracellular pathways can induce structural abnormalities in the glomerular and tubular 
compartments of the kidney which were reported in the model used in our studies. 
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Histopathological analysis demonstrated severe pathological changes that include mesangial 
expansion, interstitial fibrosis, glomerulosclerosis and increased tubular protein in the vehicle 
group which were significantly improved upon PDE1 inhibition. Shannon et al. showed that the 
histopathological changes in this model were associated with the upregulation of genes involved 
in inflammation and fibrosis [97]. In order to further understand the improvement in pathology 
upon PDE1 inhibition, we performed microarray analysis which demonstrated a reduction in 
expression of genes related to inflammation and fibrosis. However, while directionally consistent, 
these changes did not reach significance. To follow up in a more quantitative fashion, we designed 
a custom gene array focusing on the genes that were up-regulated in the disease state and down-
regulated by the compound treatment. Using RT PCR with pre-configured Taqman array card, we 
demonstrated significant changes in the expression of several genes related to inflammation 
pathway like CCL2, LCN2, SAA1 and VCAM1. They were highly upregulated in the vehicle 
group but were significantly down-regulated upon PDE1 inhibition. Genes related to fibrotic 
pathway like COL1A1 and COL1A2, COL3A1, and FN1 were significantly downregulated in 
PDE1 inhibitor treated group compare to vehicle. These data suggest potential role of PDE1 in 
inflammation and fibrosis apart from its vasodilatory function that might have contributed to the 
renal benefit. 
 
The role of PDE1 in inflammation and fibrosis has been reported in several other organ system. 
Initial evidence of potential role of PDE1 in inflammation came from the investigation of  a non-
selective PDE1 inhibitor vinpocetine. Recently, a highly selective PDE1 inhibitor ITI-124 
demonstrated a regulatory role of PDE1 in inflammatory response in microglia [57]. The authors 
demonstrated that inhibition of PDE1 resulted in >50% reduction in LPS induced increase of TNFa, 
IL-1b, and CCL2 mRNA expression both in BV2 microglial cell and also in mice specially in brain 
regions with high PDE1 expression (striatum, cortex and hippocampus). Our data extended the 
scope of anti-inflammatory effects of PDE1 inhibition to the realm of diabetic kidney disease.  
Although albuminuria and serum creatinine are widely used as primary endpoints for DKD, these 
markers are lacking direct association with the severity of morphological changes in kidneys and 
cannot be considered ideal prognostic markers [5]. The ACCORD study demonstrated that 
intensive pharmacological glycemic control can reduce the incidence of albuminuria but did not 
prevent development of CKD or progression of CKD to end-stage renal disease. Furthermore both 
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VADT or ADVANCE, which evaluated the benefits of heart disease upon intensive glycemic 
control, failed to show a statistically significant benefit for reducing HbA1c to less than 7% in 
T2DM patients. These findings underscore the necessity to predict incident and progressive CKD 
in type 2 diabetes (ACCORD trial). Faced this discrepancy, several potential prognostic and 
surrogate endpoint biomarkers for advanced DKD has received major interest. Although DKD has 
been regarded primarily a glomerular disease, recent data suggested that tubulointerstitial injury 
may have an important role in pathogenesis and progression of the disease. On that basis, KIM1 
and NGAL [137-139] have been proposed as potential candidates for tubular damage markers and 
shown to be associated with faster decline in eGFR [140]. In CKD, including DKD, NGAL is 
considered a diagnostic and prognostic marker. Bolignano et al. observed that uNGAL increased 
and correlated with the advancement of kidney disease in patients with DKD both with and without 
albuminuria [141]. Both type 1 and 2 diabetic patients showed not only higher level of urinary 
NGAL but also showed a positive correlation with albumin/creatinine ratio [142, 143]. In the post-
hoc analysis of dapagliflozin clinical trial, reduction of KIM1 has been associated with the 
renoprotective effect [144]. In our study, we found that both urinary KIM1 and NGAL were 
elevated in the AAV/Renin model and were significantly reduced (almost to the basal level) with 
PDE1 inhibitor. Interestingly, ACE inhibitor, the current standard of care for DKD, did not show 
any reduction in tubular injury markers in diabetic nephropathy patients [137]. These findings not 
only suggested that PDE1 inhibition mediated improvement of renal function, likely associated 
with direct protection of the renal tubules, but also offer either better or additive benefit with the 
standard of care. 
 
Monocyte chemoattractant protein-1 (MCP-1) and growth differentiation factor-15 (GDF-15) are 
well known cytokines that are increased in tissue injury and inflammatory states and have been 
associated in both cardiac and renal disease [145-147]. It has been shown in animal studies that in 
diabetic renal injury, increases in urinary GDF-15 were associated with proximal tubule injury 
[148]. Urinary MCP-1 levels have been reported to be significantly higher in diabetic patients.  
They correlated with albuminuria and with increased severity of tubulointerstitial lesions along 
with urinary NGAL which might suggest that MCP-1 may reflect advanced tubulointerstitial 
lesions in diabetic patients [149]. In our study, we have seen a significant progressive increase in 
both urinary MCP-1 and GDF-15 in vehicle control group which significantly reduced in the PDE1 
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treated group. Interestingly, reduction in urinary MCP-1 was observed as early as in 2wks, whereas 
it took 4wks to see an effect on GDF-15. We did not see any change in serum MCP-1 in our mouse 
study that corroborates others findings [149]. Both markers demonstrated good correlation with 
albuminuria which corroborates previous findings [148]. These data provide another confirmation 
that renal benefits as seen in this model with PDE1 inhibition might be due to the protection of 
renal proximal tubule cells. 
 
While the above urine markers provide useful prognostic information, molecular readout more 
proximal to the molecular target (PDE1) would be very useful as pharmacodynamic marker at the 
clinical drug development stage. In this context, it is reasonable to focus on cyclic nucleotides 
since they serve as direct substrates of PDE1 enzymatic activity. However, primary intracellular 
localization of cyclic nucleotides makes this task extremely challenging. cAMP and cGMP can 
exit the cell and thus can be detected in plasma or urine but regulation of these processes is poorly 
understood. Therefore, we have attempted quantification of cyclic nucleotides in urine and 
explored potential correlation of their levels with plasma concentration of PDE1 inhibitor. While 
in the relatively simple experimental system (acute effects on cyclic nucleotide levels in the urine 
of normal rat), we have found increased concentration of urine cyclic nucleotides as a result of 
treatment with PDE1 inhibitor, these relationships were not evident in the far more complex 
experimental system (chronic compound administration in the mouse model of DKD). Molecular 
mechanisms of this phenomenon are unclear. It is possible though that urine cAMP and cGMP 
concentration could be mechanistically associated with modification of secretion or reabsorption 
in the tubular cells and, therefore, with diuretic effects of PDE1 inhibitors. Indeed, we have found 
that PDE1 inhibition induced acute increase of urine volume in the normal rats. In the model of 
DKD, though, profound polyuria, typical for diabetes, has likely masked this physiological 
response. Thus, clinically important relationships between pharmacokinetic and 
pharmacodynamic parameters need further investigation. 
 
In summary, we have shown for the first time in a very severe preclinical model of diabetic 
nephropathy that inhibition of PDE1 provides renal protection associated with lowering 
albuminuria, reduction in serum creatinine levels and marked improvement in renal histopathology 
likely driven by suppression of inflammation and fibrosis as evident by gene expression analysis. 
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The urinary biomarker panel demonstrated that the improvement in renal function is primarily due 
to the protection of renal proximal tubule. While we clearly demonstrated therapeutic benefits of 
PDE1 inhibition, it is still unclear how renal PDE1 is activated in the context of DKD and what 
are the downstream mechanisms of these benefits. We addressed these two questions by adopting 
some bioinformatics tools and through in vitro experimentation. 
2.4.3 Mechanism of PDE1 activation and reno-protective effects of PDE1 inhibition 
In this section we demonstrated that TRPC6 mediated calcium influx is responsible for PDE1 
activation, and inhibition of PDE1 prevented renal cell apoptosis induced by TRPC6 activation. 
By using bioinformatics tools and publicly available CKD patients’ database we demonstrated that 
TRPC6 is upregulated in the glomerular compartment of several types of CKD including DKD. 
Using a TRPC6-overexpressing cell line, we demonstrated that activation of TRPC6 resulted in 
PDE1 activation as evident by decrease in cAMP. By using a TRPC6 small molecule inhibitor we 
demonstrated that hyperforin 9, a widely used activator is specific to TRPC6. We also 
demonstrated that TRPC6 mediated increase in calcium influx resulted in apoptosis in both human 
mesangial cell and rat isolated glomeruli which can be attenuated by both TRPC6 and PDE1 
inhibitor. This suggest that in the context of elevated intracellular calcium, inhibition of PDE1 
rendered renal benefit by attenuating apoptosis.  
 
Out of 11 family of phosphodiesterases, PDE1 is the only one that is activated by calcium.  
However, several Ca2+ entry pathways exist in cell and the specific source of calcium used for 
activation of PDE1 in the kidney is unknown. So far one report suggested that in cardiomyocyte 
PDE1 gets activated by TRPC3 mediated calcium influx[95] but no such data exist in kidney cell. 
Recently, studies have shown that disruption of calcium signaling in the kidney leads to kidney 
disease and using genetic or biochemical tools identified several channels that are important in 
renal disease [54]. Our analysis of gene expressions of the transcriptional dataset from European 
Renal cDNA Bank (ERCB) revealed TRPC6 as the most upregulated calcium channel in 
glomerular compartment of patients with different kinds of CKD, including DKD [150] . 
Interestingly, we did not see any change in the expression of major calcium channels in the tubular 
compartment. Dysregulation of calcium signaling has been implicated in the kidney disease and 
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evidence of several gain-of-function mutation in human TRPC6 channels has been implicated in 
FSGS, predominantly a glomerular disease that is characterized by massive proteinuria. The 
expression of TRPC6 in podocytes and as a component of the glomerular slit diaphragm has been 
confirmed by several studies [68, 151]. We also have found increased TRPC6 expression in the 
glomerular compartment of FSGS patients included in the ERCB dataset. Like FSGS, diabetic 
nephropathy is also characterized by loss of podocyte and proteinuria. TRPC6 has been shown to 
be increased in cultured podocyte in response to high glucose and in STZ-induced diabetic rats 
[76]. In our differential gene expression ( DEG) analysis we also have found several fold increases 
of TRPC6 expression in DKD patients from ERCB cohort. Thus, our data also support that 
increased expression of TRPC6 may be involved in number of glomerular kidney diseases. 
Admittedly, one of the limitations of the study is based on the fact that we only focused on the 
channels that has been reported in literature to be involved in kidney diseases. 
 
Based on gene expression data in CKD patients we postulated that TRPC6 is the major driver of 
calcium influx that is involved in PDE1 activation in the context of kidney disease. TRPC6 
mediated increase in intracellular calcium have been shown to induce apoptosis in multiple cell 
type through different mechanism. Soni et al. have shown in neonatal pig glomerular mesangial 
cell that hyperforin, a selective TRPC6 activator, induced cellular apoptosis via calcineurin/NFAT 
and FasL/Fas signaling pathway [152]. Inhibition of TRPC6 has been reported to protect renal 
proximal tubule cell from oxidative stress mediated cellular apoptosis [95]. Here we have 
demonstrated for the first time that in primary human mesangial cell and in rat isolated glomeruli 
activation of TRPC6 induced apoptosis in PDE1-dependent manner. By using selective inhibitor 
of both TRPC6 and PDE1 we demonstrated the crosstalk of two major signaling pathway and its 
importance in maintaining cell viability. Our data corroborates similar findings in mouse 
cardiomyocytes where it has been shown that TRPC3 is involved in PDE1C-mediated 
cardiomyocyte death [95].  
 
In summary, in this section we have demonstrated vasodilatory function upon PDE1 inhibition in 
vivo by adopting a novel technique using ear temperature as surrogate marker.  Peripheral 
vasodilation resulted in lowering of blood pressure in both normotensive and hypertensive rats. 
We also demonstrated for the first time that PDE1 inhibition leads to the renal benefit using a 
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rodent model of DKD as evident by lowering of ACR, serum creatinine and several urinary 
biomarkers. The histopathological improvement due to PDE1 inhibition were associated with and 
likely driven by inhibition of inflammation and fibrosis pathways. Using gene expression analysis 
of CKD patients, we identified TRPC6 as major channel that is upregulated in the glomeruli and, 
using human primary mesangial cell and rat isolated glomeruli, we have shown that induction of 
TRPC6 leads to apoptosis in PDE1 dependent manner. In subsequent section we asked the question 
of how TRPC6 gets activated in the diabetic environment. 
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 ROLE OF TRPC6 AND PDE1 IN THE CROSSTALK OF 
CALCIUM AND CYCLIC NUCLEOTIDE SIGNALING 
3.1 Introduction 
In the previous chapter, we have demonstrated the role of PDE1 in DKD. That, on its own, laid 
out new ideas about pathogenesis of the disease and may provide novel approaches to its 
pharmaceutical treatment. However, both from the basic science and drug discovery perspectives, 
it is important to understand how PDE1 is activated. Therefore, the current chapter is focused on 
the upstream pathways that link extracellular risk factors of DKD and PDE1. Since PDE1 is 
activated by calcium, the first obvious question relates to the source of calcium leading to PDE1 
activation. We have previously identified TRPC6 as a likely candidate. Here, going further 
upstream, we set out to link extracellular molecules/risk factors with TRPC6 and identify 
molecular mechanisms involved in opening/activation of this calcium channel. 
 
Canonical transient receptor potential channel (TRPC) is one of the major ion channels that 
regulate calcium influx into the cell from the extracellular space. Among seven structurally related 
family members, the importance of TRPC6 has been emphasized by the discovery of gain of 
function mutation in FSGS clinically manifested by massive proteinuria [68]. Proteinuria is a 
clinical feature shared by FSGS and DKD. However, while a subset of FSGS patients exhibit a 
gain-of-function mutation of TRPC6, it is likely that in DKD, certain extracellular molecules 
associated with diabetes and serving as risk factors of DKD, directly activate TRPC6. 
Comprehensive review of these risk factors is beyond the scope of this study. Major risks of DKD 
stem from the hemodynamic and metabolic directions. Thus, we decided to focus on main 
representatives of these two groups, specifically, angiotensin II and endothelin 1 on the 
hemodynamic side, and glucose and insulin on the metabolic side. Any extracellular molecule can 
activate TRPC6 via generation of diacylglycerol (DAG) or reactive oxygen species (ROS). In this 
chapter, we developed or applied novel molecular tools to address two questions: (1) What 
hemodynamic and metabolic risk factors of DKD activated TRPC6 and (2) What was the 
molecular mechanism mediating this activation. 
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Intracellular DAG can be formed either via G-protein coupled (GPCR) receptor mediated 
hydrolysis of membrane phospholipids [153] or de novo synthesis using glycolytic intermediates 
as precursors or hydrolysis of triglycerides [70, 154]. In the extremely complex diabetic milieu, 
DAG is likely to be generated by all three sources [155]. Moreover, Gq receptors can be activated 
by multiple ligands: angiotensin II (Ang II), Endothelin-1(Et-1), thromboxane, prostaglandin E2 
etc which are also abundant in diabetic milieu [72, 156, 157]. It is unknown if various Gq agonists 
lead to uniform generation of DAG and TRPC6 activation. Majority of publications used Ang II 
or a membrane-permeable DAG analog, 1-oleyl-2-acetyl-sn-glycerol (OAG) [153, 158]. While 
this generalized approach was fruitful in elucidating common signaling mechanisms, it is 
conceivable that individual Gq agonists may affect different facets of the pathway. Current 
literature strongly suggests differential pattern of activation of TRPC3, a close relative of TRPC6 
[154]. Similar studies regarding TRPC6 are needed. 
 
Reactive oxygen species (ROS) which are also abundant in diabetic milieu has also been 
implicated in the activation of TRPC6. Both angiotensin II and high glucose have been shown to 
activate TRPC6 via ROS generation [159, 160]. Kim et al, has demonstrated that ROS mobilized 
the TRPC6 channel in cultured podocytes [161, 162] and later on using pharmacological and 
genetic tools other investigators have shown that ROS dependent TRPC6 activation is the primary 
source of calcium influx in isolated glomeruli [159]. Later it was shown that the downstream 
signaling pathway involved Rac/Rho pathway and caused podocyte cytoskeleton derangement 
[163, 164]. Furthermore, in podocytes, Ang II induced apoptosis is associated with alteration of 
TRPC6 expression and Ca2+ influx [165].  
 
Similarly, in monocytes it has been shown that high glucose induced ROS activates TRPC6 and 
increase calcium influx [160]. In cultured podocytes, it has also been demonstrated that glucose 
upregulated TRPC6 and increased calcium influx [165]. These indirectly suggest that high glucose 
might be activating TRPC6 via ROS generation. However, the possibility that high glucose can 
activate TRPC6 by generating DAG through de novo synthesis pathway has been overlooked. 
Once activated TRPC6 allows influx of calcium ions into the cell which effects several 
downstream signaling pathways. For example, stimulation of TRPC6 channels has been shown to 
activate stimulus-responsive transcription factor activator protein-1 (AP-1) [166] which is at a 
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convergence point for multiple intracellular signaling pathways that operates in tissue-specific 
regulation of many biological functions [167]. TRPC6 mediated rise in calcium concentration has 
also been shown to activate calcium-dependent protein phosphatase calcineurin which 
dephosphorylates the cytoplasmic subunits of NFATc transcription factors resulting its nuclear 
translocation and upregulating many genes that are associated with neonatal glomerular mesangial 
cell apoptosis in kidney, whereas in cardiovascular biology it has been associated with  myoblast 
transformation, and pathologic cardiac modeling [152, 168]. Moreover, overexpression of either 
wild type or of gain-of-function mutations of TRPC6 that is reported in human, triggered a 
constitutive activation of NFAT-regulated gene transcription involved with focal segmental 
glomerulosclerosis [78]. TRPC6 mediated intracellular increase in calcium also has been shown 
to activate Ca2+2/calmodulin-dependent protein kinase CaMKIV along with the MAP kinase 
extracellular signal-regulated protein kinase (ERK) [169]. 
 
Our data places PDE1 into the list of downstream mechanisms that link TRPC6 and DKD. In 
previous chapters we have demonstrated that TRPC6 might be another potential channel that might 
influence the intracellular calcium required to activate PDE1. Here using heterologous expression 
model, we showed how systemic risk factors in diabetic milieu activates TRPC6. We identified 
multiple clones that have several fold higher expressions of TRPC6 and selected one clone, C11 
as functional clone based on the change in membrane potential in response to several known 
TRPC6 activator. Using small molecule, we demonstrated that this increase in membrane potential 
and corresponding calcium influx is TRPC6 specific. We also have demonstrated that several risk 
factors in diabetic milieu can increase intracellular calcium influx but differentially activate 
TRPC6. Finally, we have demonstrated that activation of TRPC6 leads to the depletion of 
intracellular cAMP. Although a large body of data exists pointing the importance of TRPC6 in the 
health of podocyte here we describe another mechanism where crosstalk between calcium and 
cyclic nucleotides that might play an important role in cellular physiology. 
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3.2 Methods and materials 
3.2.1 Reagents 
All chemicals and reagents were obtained from commercial sources. Hyperforin 9 (cat#H9791-
25MG, Sigma Aldrich, St Louis, MO), Forskolin (cat#1099, TOCRIS Chemicals) were prepared 
as either 25uM or 10mM solution with DMSO. Both Angiotensin II (cat# A9525) and 1-Oleoyl-
2-acetyl-sn-glycerol (OAG, cat# O6754) was purchased from Sigma Aldrich. The DAG sensor 
and cAMP sensor were purchased from Motana Molecular. 
3.2.2 Cell Culture 
TRPC6 overexpressed cell C11 (in the background of HEK293) cells were grown in mono layer 
culture at 37 °C in a humidified air atmosphere with 5% CO2 using DMEM/F12 media with 
250ug/ml HYGRO, 20mM Hepes, 1X NEAA, 1X NaPyruvate, 10% heat-inactivated fetal bovine 
serum, and 1% penicillin-streptomycin solution. All the experiments were performed between 
passage number 55-60. 
3.2.3 Construction of recombinant plasmid and generation of TRPC6 stable cell line 
Human TRPC6 gene was cloned using pcDNA™5/TO Mammalian Expression Vector system 
from Thermo Fisher (cat# V103320) using the manufacturer protocol. Briefly the human TRPC6 
gene was first cloned between 1492 and 2870bp flanked by ava 1 and HindIII restriction sites. The 
whole construct was then chemically transformed in E. coli DH5α™-T1R strain and was 
propagated using the condition described by the manufacturer. Clones were selected on LB agar 
plates containing 50–100 μg/mL ampicillin. Once the presence and orientation of the hTRPC6 was 
confirmed plasmid were isolated and stored in -800C. For making the stable cell line 
overexpressing hTRPC6, HEK293 cells were grown at approximately 60% confluent.  Following 
day they were co-transfected with pcDNA™5/TO construct and pcDNA™6/TR at a ratio of 6:1 
using lipofectamine 2000 (cat# 11668030). After transfection, fresh medium was added, and the 
cells were allowed to recover for 48 hours before induction. The final clones were selected based 
on a final concentration of 250μg/mL of hygromycin to the media. 10–20 clones were selected and 
analyzed for the presence and orientation of TRPC6 insert and plasmid vector.  
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3.2.4 Adenoviral construction of GCamp2 Ca sensor with hTRPC6 
In order to monitor the calcium influx a hybrid construct was created by ligating GCamp2 sequence 
to the 5’ end of the hTRPC6 under the CMV promoter. The hybrid construct was cloned into the 
pcDNA5/TO plasmid vector using the above protocol. Once the plasmid sequence and orientation 
confirmed the whole construct was commercially made by Vector Bio Labs. The titer was 
confirmed as 5 X 1013 gc. 
3.2.5 Membrane potential assay 
FLIPR assay development was performed following manufacturer’s protocol (Molecular Devices, 
Sunnyvale, CA). Briefly, the day before the experiment TRPC6 overexpressed clones or HEK293 
cells were seeded at 30K, 40K, 50K or 60K cells per well on Biocoat 96well plate (BE01770) for 
overnight incubation in cell culture incubator (5%CO2, 37°C). Cell plates were loaded with 50ul 
of assay buffer containing 1× membrane-potential dye component A and incubated for 1hr. For 
making the stock solution of AngII and OAG, 1mM stock solution was prepared using the water 
and DMSO respectively. Either a single concertation was prepared, or a serial dilution was made 
to prepare the different doses of stimuli with their respective vehicle. For compound TRPC6 
inhibitor a serial dilution was made using DMSO. The stimuli were prepared in 96 well plate and 
placed in the ‘reservoir’ section of the FLIPR system. The plate containing the cells and loading 
dye was placed in the on the platform of FLIPR384 (Molecular Devices), and the fluorescence 
signal was read with excitation/emission spectrum at 488/540 nm. The FLIPR tetra has a fully 
automated High-Speed Distributed Motion (HSDM) Thermo LAS microplate assay system which 
was used to conduct the HTS campaign. Measurements were made at 5s intervals. Basal 
fluorescence was measured for 15–30s, followed by addition of 5ul of the test stimuli and 
measurement of fluorescence for 300s. Raw fluorescence readings were first converted to response 
over baseline using the analysis tool of Screenworks 3.1.1.4 (Molecular Devices). The result was 
expressed relative to the maximum increase in fluorescence of control responses. 
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3.2.6 Measurement of Calcium influx in cell using FLIPR calcium assay kit 
 
About 50K cells of TRPC6 stable cell line C11 were plated in each well of a black walled 96-well 
imaging plates and cultured for 24 h. The calcium dye used in the experiment was commercially 
available FLIPR Calcium 6 no-wash dye (Molecular Devices) that was prepared by dissolving the 
contents of one Component A vial by adding 10 ml of Component B or 1X HBSS Buffer plus 20 
mM HEPES in physiological salt solution as per manufacturer’s instructions. Before adding the 
appropriate stimuli growth media was completely removed and replaced with 100ul of the prepared 
reagent and incubated for 2hrs in the dark at 37˚C. The plate was placed on the platform of FLIPR 
machine and the reagents were added using the automated injector system. The immediate change 
in fluorescence was measured using excitation 470–495 nm, and emission 515–575 nm every 5s 
after addition of test compounds. Raw fluorescence readings were first converted to response over 
baseline using the analysis tool of Screenworks 3.1.1.4 (Molecular Devices). The result was 
expressed relative to the maximum increase in fluorescence of control responses. 
3.2.7 DAG measurement  
C11 cells were plated at 20K per well in a 96-well black walled plate and transduced with either 
DAG sensing protein (cat#D0300G, BacMam; Montana Molecular, Bozeman, MT) or cADDi 
cAMP senor (cat#during split and grown for 24hrs.  Next day growth medium was removed and 
replaced with 100ul of PBS. Cells were mounted on a FLIPR station and stimulated with test 
compounds and fluorescent signal was captured at for 5 minutes at excitation 470–495 nm, 
emission 515–575 nm. Data was expressed as relative light units and the AUC was calculated 
using the Screenwork software. 
3.2.8 cAMP measurement  
A cAMP upward mNeon Green cADDis biosensor expressed under a CMV promoter was obtained 
from Montana Molecular (U0200G), and delivered by transduction with BacMam, a baculovirus 
modified to infect C11 cells. The cells were incubated in the presence of 2 mM sodium butyrate 
for 48 hours after transduction according to manufacturer’s specifications before imaging. After 
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confirming the expression of the cAMP sensor cells were treated with test compounds. In case 
compound treatment, cells were pre-incubated with compounds for 1hr before the experiment. 
Some cultures were supplemented with 10 μM forskolin for 30 minutes as positive control. 
Following the treatment with either test compounds or the positive control cells were fixed with 
4% formaldehyde and stained with Hoechst dye. Cell images were captured using a Cellomics 
Arrayscan VTI and analyzed with the Target Activation BioApplication reading in two channels 
at a magnification of ×10. An algorithm was used to identify objects by nuclear staining with 
Hoescht dye at 365nm, and cAMP was determined using 475nm wavelength. All fluorescent 
intensities are displayed as relative fluorescent units. 
3.3 Results 
3.3.1 Generation and selection of TRPC6-overexpressing stable cell line 
As a first step towards the generation of stable TRPC6 overexpressing cell line, human embryonic 
kidney 293T cells (HEK293T) were transiently transfected with plasmid containing human TRPC6. 
Clones were selected based on their hygromycin resistance and expression of TRPC6 was 
measured using standard RT-PCR as shown in Fig 3.1. Based on relative expression of TRPC6, 
C1, C11, and C6 clones were selected to further evaluate their function. Membrane potential assay 
is a fluorescence-based method that does not directly measure ionic current, rather it measures the 
membrane potential-dependent changes of fluorescence signals as a result of ionic flux. As 
described in the Methods and Materials, the selected clones, including non-transfected HEK293T 
cells, were treated with either water or angiotensin II. Following the incubation with the dye, the 
fluorescent signal was captured by the FLIPR tetra high throughput imaging system. No changes 
in fluorescence was detected in HEK293 cell in response to 1uM of Ang II. However, C11 clone 
demonstrated a steep increase in fluorescent signal in response to Ang II-mediated depolarization, 
and the signal remained elevated during the time of the recording. The other two clones, C1 and 
C6, did not show any changes in the fluorescence signal (Fig 3.2A). Interestingly, even C1 had 
higher fold of TRPC6 expression compare to C11 but did not elicit any change in depolarization 
in response to angiotensin II. We further confirm this observation by treating the C11 along with 
C6 and naïve HEK293 cells with different doses of angiotensin II. As we have seen before, neither 
 
 
 
87 
 
naïve HEK293 nor C6 showed any change in the fluorescent signal. However, C11 demonstrated 
dose-dependent membrane depolarization (Fig 3.3). To confirm that AngII-mediated response is 
TRPC6 dependent, the cells were preincubated with a TRPC6-selective small molecule inhibitor 
and then treated with AngII. As shown in the Fig 4, TRPC6 inhibitor dose-  
 
Figure 3.1.  TRPC6 gene expression in the stable HEK293 cell line. Following transfection 
with hTRPC6 construct individual clones were selected in the presence of hygromycin . Twenty-
four clones were selected, and RNA was isolated. Using human TRPC6/GAPDH taqman primer 
pair gene expression was analyzed. A) hTRPC6 plasmid map. B) Fold increase in TRPC6 
expression. 
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Figure 3.2. Comparison of fluorescent signal response of selected TRPC6 clones to 
membrane potential change during AngII stimulation. WT HEK293, clone 1(C-1), clone 
11(C-11) and clone 6(C-6) were grown over night in poly-D-Lysine coated 96 well plate. After 
incubating with membrane potential dye for 30min cells were treated with 1uM angiotensin II 
and calcium signal was measured using FLIPR tetra high throughput screening system. 
 
dependently inhibits AngII-mediated membrane depolarization. Finally, we tested C11 against 
another well-known TRPC6 activator OAG and showed that C11 dose-dependently responded to 
OAG-induced change in membrane potential (Fig 3.5). The dose response study showed that, in 
C11 clone, OAG dose-dependently induced membrane depolarization at cell density between 30K-
40K (Fig 3.5). Cell number higher than 40K did not show any response to Ang II stimulation. 
Figure 3.3. Membrane potential assay. About 30K cells of naïve HEK293 along with C6 and 
C11 clones were plated in a 96-well plate. After an overnight incubation the cells were incubated 
with membrane potential dye for 30 minutes. Cells were then treated with different concentration 
of AngII and the change in the fluorescent was captured in FLIPR. Relative fluorescence units 
(RFU) and were calculated from the maximum fluorescence value (Max) after addition of AngII 
immediately before addition of AngII. Data shown represent the mean ± S.E.M. 
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Taken together, these data suggested that the selected clone C11 is functionally active clone among 
others with similar level of TRPC6 gene expression.  
3.3.2 Hyperforin 9 induced calcium flux in HEK293 cells in TRPC6-dependent manner 
As a next step, we aimed to confirm that hyperforin 9, a widely used TRPC6 activator, induces 
calcium influx in a TRPC6-dependent manner. To achieve this goal, we constructed a plasmid 
whereby GCamp2, a calcium biosensor, was fused in the 3’ end of human TRPC6 gene and cloned 
into pcDNA3.1 vector under CMV promoter (Fig 3.6 A). The whole construct was then packaged 
in an adenovirus for the ease of delivering to the cell. Following infection, HEK293 cells were 
treated  
 
Figure 3.4. TRPC6 inhibitor inhibits AngII mediated change in membrane polarization. 
About 30K cells of C11 clones were plated in a 96-well plate. After an overnight incubation the 
cells were pre-incubated with TRPC6 inhibitor for 1hr and with membrane potential dye for 30 
minutes. Cells were then treated with 1uM of AngII and the change in the fluorescent was 
captured in FLIPR for 5minutes. Relative fluorescence units (RFU) were calculated from the 
maximum fluorescence value (Max) after addition of AngII and the minimum fluorescence 
value (Min) immediately before addition of AngII. Data shown represent the mean ± S.E.M. 
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with hyperforin 9, and the fluorescence signal was captured using a laser scanning confocal 
microscope. Hyperforin 9-treated cells have shown increased fluorescence signal within 30 sec of 
addition, and it reached its peak within 60s. To test if this signal is indeed mediated by TRPC6 
activation, we pre-treated the cells for 2hr with TRPC6-specific small molecule inhibitor  
 
 
 
Figure 3.5. Effect of cell density on the fluorescence response of membrane potential dye 
in TRPC6 clone 11 against different stimuli. Different amount of clone 11 were plated in 
poly-D-lysine coated plate. Following loading with membrane potential dye for 30min cells 
were stimulated with different concentration of A) Angiotensin II (AngII) and B) 1-oleyl-2-
acetyl-sn-glycerol (OAG). Fluorescent signal was captured in FLIPR for 5minutes. Relative 
fluorescence units (RFU) were calculated from the maximum fluorescence value (Max) after 
addition of AngII and the minimum fluorescence value (Min) immediately before addition of 
AngII. Data shown represent the mean ± S.E.M. 
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Figure 3.6. TRPC6 inhibitor inhibits hyperforin 9 induced calcium influx in C11. The 
hybrid construct to monitor the calcium signal was created by fusing GCamp2 coding sequence 
to the human TRPC6 and cloned in adeno viral vector. HECK293 cells were infected with 
adenoviral TRPC6-Ca sensor hybrid. Following overnight infection, the cells were treated with 
50uM Hyp9 in presence or absence of TRPC6 inhibitor. A. Genetic map for the hybrid construct 
B) upper panel: Time lapse fluorescent signal following Hyp9 stimulation. B) Lower panel: The 
fluorescence signal is inhibited by the pre-treatment of 10uM of TRPC6 inhibitor. C. 
Quantitative representation of the fluorescent signal. 
 
 
and then treated the cells with hyperforin 9. As shown in the lower panel of figure 6B, TRPC6 
inhibitor-treated cells showed complete attenuation of the fluorescent signal. Taken together, this 
suggests that hyperforin 9 induced calcium influx in TRPP6-dependent manner. 
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3.3.3 Several risk factors of DKD caused increased calcium influx in TRPC6-
overexpressing cell line 
Published studies have shown that several risk factors in diabetic milieu like AngII, endothelin 1, 
glucose can cause increased calcium influx in the cell. To evaluate the involvement of TRPC6, we 
treated C11 clone with several molecules representing these known risk factors and measured 
intracellular calcium release using high-throughput Fluorometric Imaging Plate Reader (FLIPR). 
About 50K cells were plated. and after overnight incubation with various “risk factor’ molecules, 
cells were incubated with calcium 6 assay dye for 30 minutes, and fluorescence signal was captured 
with FLIPR. Representative fluorescence traces illustrating cellular response to different stimuli 
in C11 clone are shown in Fig 3.7. The corresponding solvent for each reagent was used as negative 
control. Carbachol and hyperforin 9 were used as positive controls. Incubation with water did not 
induce any change of fluorescence, whereas incubation with carbachol produced dose-dependent 
spikes in the fluorescent signal (fig 3.7).  Out of the all stimuli tested, hyperforin 9 demonstrated 
the highest amplitude in the peak of calcium signal and an extended duration similar to glucose 
(Fig 3.7A). Among the hemodynamic risk factors, both Ang II and endothelin-1 demonstrated 
increased calcium influx (Fig 3.7B and 3.7C). Interestingly, even though they belong to the same 
class of vasoactive amines, endothlin-1 demonstrated a higher amplitude and instant increase in 
intracellular calcium whereas the response to Ang II was much delayed with much lower amplitude 
in the signal at the same concentration. Among the metabolic risk factors, glucose dose- 
dependently increased intracellular calcium and demonstrated extended response, whereas insulin 
did not induce any response (Fig 3.7D and Fig 3.7E). These data suggested that not all the risk 
factors in diabetic milieu induce similar response in intracellular calcium.  
3.3.4 Diabetic risk factors differentially activate TRPC6  
It has been demonstrated that both reactive oxygen species (ROS) and diacylglycerol (DAG) 
production are the key factors for activating TRPC6 [153, 170]. As we have demonstrated in the 
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Figure 3.7. Representative FLIPR traces showing changes in calcium influx in C11 in 
response to diabetic risk factors. Cells were incubated with Calcium 6 dyes from Molecular 
Devices for 30 minutes before the treatment. Fluorescence measurements were taken for 30 
seconds before addition of different stimuli. FLIPR traces showing change in fluorescence after 
addition of different doses of A. Hyperforin 9, B. Angiotensin II, C. Endothelin-1, D. Glucose 
and   E. Insulin. In each cases water or DMSO were used as negative control and carbachol was 
used as positive control. 
 
earlier section that systemic risk factors in diabetic milieu triggers TRPC6 mediated calcium influx, 
we next moved to evaluate if they differentially activate TRPC6. To evaluate the DAG-mediated 
activation of TRPC6, we employed a fluorescent downward DAG biosensor which is a fusion of 
a PKC-d fragment with circular permuted enhanced green fluorescent protein (GFP). Reactive 
oxygen species (ROS) were detected using cell-permeable dye, CELL ROX-Green, which is 
oxidized by O2– and •OH and the signal was captured by high throughput imaging platform called 
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Cellomics. Before proceeding with the actual risk factors, we tested detection assays using positive 
control. For DAG production, C11 cells were infected with mixture of Baculoviral construct of 
DAG sensor and muscarinic receptor M1 as described in the Methods. The change in fluorescence 
due to carbachol mediated DAG synthesis was captured by FLIPR. Carbachol demonstrated a 
rapid production of DAG soon after the compound injection. The calculated AUC of the 
fluorescent signal showed significantly higher DAG levels compared to water (Fig 3.8A). We then 
used hyperforin 9 to test if it induces any DAG production. Following infection with DAG sensor, 
plates were loaded to FLIPR chamber, and soon after adding hyperforin 9, dose dependent changes 
in the fluorescent signal was detected (Fig 3.8B). To measure ROS, C11 cells were treated with 
tert-Butyl hydroperoxide (TBHP) for 1hr. Before fixation with paraformaldehyde, cells were 
incubated with CELL ROX green dye and Hoechst stain for 30 minutes. The fluorescent signal 
was detected with Cellomics imaging system at 665nm. TBHP demonstrated dose-dependent 
production of ROS which was attenuated by treatment with a redox scavenger N-acetyl-L-cysteine 
(NAC), showing dose-dependent inhibition of fluorescence signal (Fig 3.9). After confirming that 
we have methods to detect DAG and ROS, we tested several diabetic risk factors in our system. 
To explore the risk factor-mediated DAG production, C11 cells were treated with different 
concentration of AngII, Et-1, glucose and insulin. As shown in Fig 11, glucose and Et-1 dose 
dependently induce DAG production whereas AngII did not. When tested for ROS production, 
hyperforin 9 did not induce any ROS generation. This would be the first time we demonstrated 
that hyperforin 9 activated TRPC6 via DAG production but not via ROS (Fig 11). When tested for 
differential activation of TRPC6 by the systemic risk factors, we found that Ang II activated 
TRPC6 via ROS generation but not via DAG production. In our experimental system, glucose 
demonstrated activation of TRPC6 via DAG production in dose-dependent manner but did not 
induce any ROS, whereas insulin induced neither DAG nor ROS (Fig 3.10 and Fig 3.11).  
 
To confirm these findings in more complex system, we ran similar experiments in isolated rat 
glomeruli. Rat glomeruli were isolated as described in Methods and Materials. About 60-70 
glomeruli were plated in a 96-well plate and, following overnight incubation in the media, they 
were treated with different agents to induce ROS, and the fluorescent signal was captured via 
Cellomics. As shown in Fig 12, TBHP dose-dependently produced ROS which can be inhibited 
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by NAC. AngII dose-dependently induced ROS within 1hr, and the signal remained elevated for 
4hrs. Interestingly, THBP shown much higher level of ROS compare to AngII in one hour but the 
Figure 3.8. Hyperforin 9 induce transient intracellular diacylglycerol (DAG) in C11. Cells 
were plated overnight after infecting with baculoviral DAG construct. For testing carbachol 
the cells were also co-infected with muscarinic receptor M1. After overnight incubation cells 
were loaded in FLIPR chamber and treated with respective stimuli and the fluorescent signal 
was captured for 10 minutes. Baseline fluorescent signal was captured for 30s before the 
treatment. The traces show fluorescence changes following treatment with A. Carbachol and B. 
Hyperforin 9. 
 
signal came down in 4hr. Like in C11 clone, glucose did not induced ROS even with longer 
incubation (Fig 3.12 B). We could not explore DAG production in isolated glomeruli using our 
existing DAG sensor as it failed to generate any signal with repeated effort.  
3.3.5 Activation of TRPC6 caused depletion of cellular cAMP level 
We used a genetically encoded single-color cAMP bio-sensor cADDis, that has been validated 
previously [9] to evaluate the cellular cAMP level upon TRPC6 activation. To optimize the time, 
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TRPC6 overexpressed cells  (C11 clone) were treated with 50uM of forskolin and incubated for 5, 
10, 20 and 30 minutes. After incubation, cells were fixed with 4% paraformaldehyde and the 
Figure 3.9. N-acetyl cysteine (NAC) attenuates tetra butyl hydrogen peroxide (TBHP) 
induced ROS in C11. Cells were treated with different doses of A) TBHP alone or with B) 
NAC for 1hr. Cells were fixed with 4% paraformaldehyde and ROS was detected using CELL 
ROX dye and the fluorescence signal was captured using cellomics. Qualitative analysis 
showing the fold induction as calculated by normalizing with respective control well. Data 
presented are the mean±s.e.m. p value calculated by one way ANOVA (N=4). 
 
fluorescent signal was measured using Cellomic high throughput image analyzer. Forskolin 
showed a time-dependent increase in fluorescent signal that reached significance at 20 minutes, 
and the signal started to decrease at 30 minute (fig 3.13). To evaluate the effect of TRPC6 
activation on cAMP level, clone C11 was treated with two different doses of hyperforin 9 in the 
presence or absence of forskolin. As shown in the Fig 13,   forskolin significantly increased cAMP 
production in a dose-dependent manner. hyperforin9 caused reduction in the cAMP concentration. 
Hyperforin9 also significantly decreased cAMP in presence of forskolin (Fig 13). However, no 
obvious dose dependence was observed. Thus, it demonstrated that TRPC6-mediated increase in 
intracellular calcium resulted in the depletion of cellular cAMP (likely via activation of PDE1).  
3.4 Discussion 
In the previous chapter, we have identified TRPC6 as a likely source of calcium activating PDE1. 
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Figure 3.10. Differential response in DAG signal by diabetic risk factors in activation of 
TRPC6. Cells were plated overnight after infecting with baculoviral DAG construct. After 
overnight incubation cells were loaded in FLIPR chamber and treated with different doses of 
respective stimuli and the fluorescent signal was captured for 10 minutes. Baseline fluorescent 
signal was captured for 10s before the treatment. The traces show fluorescence changes 
following treatment with A. AngII and B. ET-1, C. Glucose and D. Insulin. 
 
 
Figure 3.11. Differential response of TRPC6 activators in generating ROS in C11. Cells 
were treated with various doses of different TRPC6 activators for 1hr. Cells were fixed with 4% 
paraformaldehyde and ROS was detected using CELL ROX dye and the fluorescence signal was 
captured using cellomics. Qualitative analysis showing the fold change in fluorescent by A) 
AngII and B) Hyperforin 9 or endothelin 1 as calculated by normalizing with respective control 
well. Data presented are the mean ± SEM. p value calculated by one way ANOVA (N=8). 
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Figure 3.12. ROS signal in isolated glomeruli as assessed by CEL ROX dye. Equal number 
of glomeruli were plated in 96well plate and incubated with different ROS producing agent for 
1hr. Following incubation and live Hoechst staining fluorescent signal was captured by 
Cellomics. Qualitative analysis showing the fold change in fluorescent signal as calculated by 
normalizing with respective control well following treatment with several doses of A) TBHP 
alone or with NAC,. B) Isolated glomeruli was treated with different ROS producing agents and 
incubated for 1 and 4hrs. Following incubation and live Hoechst staining fluorescent signal was 
captured by Cellomics. Qualitative analysis showing the fold change in fluorescent signal as 
calculated by normalizing with respective control Data presented are the mean ± s.e.m. p value 
calculated by one way ANOVA (N=8). 
 
Figure 3.13. Detection of cAMP using green upward cAMP sensor. A) C11 cells were 
infected with baculoviral construct containing cAMP biosensor. Following overnight 
incubation cells were treated with 50uM forskolin and fluorescent signal was captured after 5, 
10, 20 and 30 minutes incubation. B) C11 cells were incubated with forskolin or hyperforin9 or 
in combination with both.  Fluorescent signal was captured using Cellomics after fixing the cells 
with 4% paraformaldehyde. Data presented are the mean ± SEM. p value calculated by one way 
ANOVA (N=8). 
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In the present study, we investigated upstream mechanisms of TRPC6 activation. Specifically, 
using human embryonic kidney (HEK) cell expression model we investigated how/whether 
systemic risk factors of DKD interacted with TRPC6.  
 
We identified multiple clones over-expressing TRPC6 and selected one clone, C11, based on the 
change in membrane potential in response to several known TRPC6 activators. Using small 
molecule TRPC6 inhibitor, we demonstrated that this increase in membrane potential and 
corresponding calcium influx were TRPC6-specific. We also have demonstrated that several risk 
factors of DKD can increase intracellular calcium influx but differentially activate TRPC6. Finally, 
we have demonstrated that activation of TRPC6 leads to the depletion of intracellular cAMP.  
 
The role TRPC6 in chronic kidney disease has been of interest for many years since the discovery 
of gain-of-function mutation related to FSGS [68]. Using heterologous system and in vivo models, 
several reports have emphasized its role in regulating calcium influx and contribution in both 
cardiac hypertrophy and renal diseases [75, 171, 172]. Recent animal studies also demonstrated its 
involvement in the pathophysiology of DKD [77, 173, 174]. We also have reported in the previous 
chapter that TRPC6 expression is higher in the glomeruli of several form of CKDs including DKD 
in human. We also have demonstrated that activation of TRPC6 leads to renal cell apoptosis in 
PDE1 dependent manner. However, it is unclear what systemic risk factors activate TRPC6 and 
what are specific molecular mechanisms of TRPC6 activation. Here we set out to examine how 
these factors activate TRPC6 using biosensor technology in the cell-based systems. 
 
Multiple researchers have shown enhanced calcium influx and associated increase in current as 
demonstrated by patch clamp using heterologous expression of TRPC6 in various cell lines 
including HEK293 [153, 175, 176]. Traditional patch-clamp has been the standard method for 
monitoring the ion channel activity.  Several other techniques including radioligand binding , 
radio-active flux assay or optical recording are currently accepted methods for investigating the 
fucntion of ion channels [177]. Fluorescent readouts are widely used both to monitor intracellular 
ion concentration and to measure membrane potential [177-179]. The principal behind the 
membrane potential assay is that any ionic flux across the membrane will result in the change in 
membrane potential which causes the redistribution of the dye and thus changes in the fluorescence. 
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They also have demonstrated a good correlation with the traditional patch clamping [177]. Here 
we generated similar heterologous system and used membrane potential as surrogate to calcium 
influx. Several stable cell lines were selected based on the gene expression. When tested for 
functional readout, only one clone, C11, showed positive response in membrane potential assay. 
Using this clone, we tested TRPC6-related activities of several DKD risk factors. For obvious 
reason, comprehensive investigation of multiple risk factors was not practical. Therefore, we 
decided to focus on two main groups of molecules: representing hemodynamic risk factors 
(angiotensin II and endothelin 1) and representing metabolic risk factors (glucose and insulin). In 
each case, we asked if a given extracellular molecule affected membrane potential and, if yes, what 
intracellular signaling molecule(s) mediated this effect. The former was assessed by changes in 
membrane potential, while the latter focused on DAG and/or ROS production as the main 
mechanisms of TRPC6 activation. As a positive control, we demonstrated that ROS, associated 
with several TRPC activators, and OAG, a DAG analog, modulated membrane potential dose-
dependently in C11 corroborating published data [180]. 
 
Angiotensin II (AngII) has been shown to induce calcium influx in podocytes and in vascular 
smooth muscle cell of the small arteries and afferent arterioles [181]. It has also been shown that, 
at least in podocytes, AngII-mediated increase in calcium is TRPC6 dependent [170]. We also 
have demonstrated that AngII dose-dependently induced membrane depolarization in C11. Using 
a small molecule TRPC6 inhibitor and multiple known TRPC6 activators, we confirmed that both 
the calcium influx and membrane potential is indeed TRPC6 specific. Our data corroborated the 
fact that AngII, after binding to AT1R, a GPCR, activates TRPC6 by ROS generation[182]. 
 
Another mediator of hemodynamic stress, endothelin 1 (ET1), has been shown to increase calcium 
current and upregulate TRPC6 and induce hypertrophy in cardiomyocyte in calcineurin-NFAT 
dependent manner [183] but the mechanism of activation was not addressed. In our hands, ET-1 
dose-dependently increased calcium influx and activated TRPC6 via DAG production but did not 
induce any ROS production. Interestingly we found that AngII activates TRPC6 via ROS 
generation, which corroborates others findings [159]. Unlike ET-1 it did not induce DAG 
production. Although both binds to the similar class of GPCRs and exert similar physiological 
effect, vasoconstriction, through elevation of calcium, the interim signaling pathways might be 
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different. Another observation we found in this study is that the amplitude of calcium signal is 
much higher in ET-1 compare to AngII. Further studies are needed to elucidate the detailed 
mechanism.  
 
Among metabolic risk factors of DKD, plasma glucose and insulin are, arguably, playing the major 
role. While hyperglycemia is a broadly accepted cause od glucotoxicity, leading to the end-organ 
damage, insulin can play dual role as a factor reducing blood glucose levels thereby acting as a 
protective factor and, in the context of selective insulin resistance, also contributing to end-organ 
damage. Both have glucose and insulin been shown to activate TRPC6. Hhigh glucose has been 
shown to increases OAG-induced calcium current and upregulate TRPC6 in monocytes and 
platelets [80, 160]. We have found that glucose-induced, TRPC6-mediated increase in calcium 
influx is attributed to the DAG production but not ROS. This contradicts the data published by 
several authors that showed that glucose-mediated TRPC6 activation is ROS dependent [182]. 
This could be attributed to the use of two different cell types. Intracellular calcium influx did not 
change with insulin treatment nor it produces any DAG or ROS. Our data showed that although 
glucose and insulin are both risk factors for diabetic condition, glucose might be playing a role in 
TRPC6 mediated pathophysiology of DKD, while effects of insulin could be mediated by other 
mechanisms. 
 
Thus, we have elucidated certain aspects of upstream activation of TRPC6 in a context of 
metabolic disturbances. What is happening downstream? Once activated, TRPC6 activates 
multiple signaling pathways. Calcium flux leads to activation of protein phosphatase calcineurin. 
Calcineurin, in turn, activates a transcription factor NFAT that upregulates several disease related 
genes. In addition to that,  we identified PDE1 as another potential downstream effector  of TRPC6, 
thereby connecting two second messenger systems, calcium and cyclic nucleotides . Among all 
the phosphodiesterase, PDE1 is the only one that is activated by calcium/calmodulin.  Recently, 
Zhang et al showed that AngII mediated activation of PDE1 leads to the reduction of cAMP in 
cardiomyocyte and this requires TRPC3 [88]. We have shown in the previous chapter that TRPC6-
mediated apoptosis can be attenuated by blocking PDE1. Thus, we confirmed that in renal cells, 
TRPC6 is associated with the PDE1-mediated apoptosis. Here, we provided some mechanistic 
connection that the cell death is associated with the depletion of cAMP. We showed that hyperforin 
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9-mediated TRPC6 activation resulted in depletion of cAMP implying that increased intracellular 
calcium activates PDE1 leading to depletion of cAMP. We also demonstrated that in human 
mesangial cells all three isoforms of PDE1 are upregulated by hyperforin 9. 
 
Mechanisms of DKD are multifactorial. Elevated level of calcium, DAG and ROS are all thought 
to contribute to the pathogenesis of DKD. In our hands, glucose did not show any ROS generation, 
while other reports have shown it can induce ROS. We have demonstrated that glucose can activate 
TRPC6 by DAG production. Elevated levels of AngII and Et-1 in diabetic patients is known [72]. 
All these can contribute to the activation of TRPC6. Our studies for the first time connected the 
diabetic risk factors with activation of TRPC6. Our studies also have shown a crosstalk between 
two second messengers, calcium and cyclin nucleotides. Earlier we have shown pre-clinical 
evidence where inhibiting PDE1 exerted benefit in the animal mode of DKD. Here we provided 
mechanistic evidence of activation of PDE1 by the systemic risk factors that involves TRPC6. One 
of the limitations of this study is the lack of either pharmacological or genetic evidence of 
involvement of PDE1 in depletion of cAMP. Although we showed that hyperforin mediated 
increase in calcium is TRPC6 specific, but the depletion of cAMP could be due to potential non-
specific action of hyperforin. Further studies are required to show the specificity. The lack of 
reliable cGMP biosensor also precluded us from investigation of potential mechanistic link 
between TRPC6, PDE1, and cGMP. More research is needed to interrogate this pathway. However, 
available data still provide sufficient evidence of a crosstalk between TRPC6 and PDE1 and their 
potential role in pathogenesis of DKD. 
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 TRANSLATING ANIMAL TO HUMAN; USE OF 
COMPUTATIONAL BIOLOGY IN UNDERSTANDING DIABETIC 
KIDNEY DISEASE 
4.1 Introduction 
In our earlier chapters we described a novel role of PDE1 in a mouse model of DKD and 
demonstrated that systemic risk factors of diabetes activate PDE1 in TRPC6 dependent manner. 
However, without conducting a clinical trial it is hard to predict whether this finding will translate 
to humans. This chapter describes the use of computational biology which was applied to renal 
gene expression, and histopathological data as well as clinical biomarkers from the DKD patients, 
in order to evaluate the pre-clinical to clinical translation. 
 
DKD is the leading cause of chronic kidney disease and in the US its prevalence has progressively 
increased over the past few decades. Despite current treatment strategies for optimizing glycemic 
and blood pressure, DKD still contributes to almost one-half of all cases of end-stage renal disease 
and becoming a major medical burden in the United States. Development of new therapeutic 
interventions for DKD requires better understanding of the pathophysiology of the disease.  
The use of genome wide Genome-wide transcriptome analysis kidney expression arrays recently 
advanced our understanding of DKD and provided insights into disease pathogenesis, and 
identification of biomarkers for progression or treatment response. Woroniecka et al, described a 
comprehensive catalog of gene-expression changes in human diabetic kidney biopsy samples using 
micro-dissected glomeruli and tubule samples and identified some novel pathways as well as 
confirmed some known pathways [82].  Several studies have been published based on the gene 
expression analysis from the European Renal cDNA Bank, a large collection of renal biopsies 
comprising of  micro-dissected glomeruli and tubule segments from CKD patients They identified 
Janus kinase1/2/signal transduced and activator of transcription (STAT), nuclear factor NFB and 
Wnt/b catenin as major pathways altered in DKD [184-187]. But identification of a consensus sets 
of gene in multiple dataset is still lacking. 
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Deciphering the pathogenesis of DKD is not straightforward and has multiple challenges. The 
complexity stems from the interaction of hyperglycemia, hypertension and renal hemodynamics 
and later through the involvement of proinflammatory factors and immune cell infiltration, makes 
it difficult to identify a single causative mechanism [188] . Second, the complex architecture and 
heterogenous cell populations of the kidney poses another challenge. The functional unit of the 
kidney, called the nephron, has a highly ordered structure, consisting of several specialized cell 
types. The important major components of the nephron are the glomeruli, which is functional 
barrier and the proximal and distal tubules that absorbs or excretes solutes. Specialized cells along 
the nephron include endothelium, mesangial cells, podocytes, and epithelial cells should be 
accompanied by corresponding regional variation in gene expression patterns [189]. In that context 
the gene expression analysis of the whole kidney often misinforms the role of specific cell types 
in the disease process. Third, DKD is clinically diagnosed by albuminuria but often the patients 
don’t progress to ESRD which makes it challenging to associate the molecular changes to the 
disease progression. Moreover, the confirmatory diagnosis of DKD is still based on histopathology 
assessment which, most of the time, is not available thus making correlation of the clinical 
phenotype to renal structural changes difficult. Renal transcriptomic analysis of DKD patients 
sometimes does not provide relevant information as the alteration in a gene expression does not 
necessarily lead to proportionate changes in protein production.. To overcome some of these issues, 
the kidney molecular signature linked to histopathology constitutes a systems biology approach 
which is becoming the mainstream to understand the pathophysiology of DKD. For example, using 
cortical interstitial fractional volume (VvInt), an index of tubule-interstitial damage and 
compartment-specific gene expression profiling from CKD patients, Nair et al demonstrated the 
early molecular signature can be linked to long-term disease progression [76]. In a separate study 
Beckerman et al., identified key driver modules from kidney expression data which correlated with 
renal structural changes rather than functional GFR [77]. These data demonstrate that relating 
transcriptomic data with histological features, provides better understanding of DKD progression 
rather than relying on molecular data alone. 
 
Finally, a severe limitation in finding a therapeutic intervention is the lack of animal models that 
accurately recapitulate human disease. Animal models often fail to reflect the diversity of the DKD 
population but also there is often a mismatch between endpoints measured in animals versus 
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humans. For example, any drug discovery process to evaluate an anti-fibrotic drug relies on the 
multiple histological, histochemical and biochemical parameters in animals whereas in clinic the 
more restrictive end points would be mortality, glomerular filtration or proteinuria. Also, most 
animal models demonstrate changes of early diabetic glomerulopathy, but they fail to capture later 
structural changes, including glomerulosclerosis, advanced tubulointerstitial fibrosis caused by 
chronic diabetes, and eventually renal function decline. These types of cross-species differences 
form barriers to translational research that ultimately hinder the success of clinical trials. Therefore, 
there is an urgent need to develop methodologies for reducing the gap between cross-species 
translational research. 
 
We have used three publicly available gene expression datasets from DKD patients to find a 
consensus set of causal genes. The canonical pathway, disease and function analysis revealed the 
association of an inflammatory and immune response signature with DKD. Furthermore, we have 
analyzed the correlation coefficient density of the set of genes with individual clinical and 
histopathological features of DKD patients and used that data to develop a model for assessment 
of translatability of animal data to humans and provided two examples of this approach.  
4.2 Methods and materials 
4.2.1 Gene expression omnibus datasets.  
The Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/gds) hosted by the National 
Center of Biotechnology Information contains high-throughput gene expression datasets deposited 
by many authors. We selected potential GEO datasets according to the following inclusion criteria: 
1) specimens had histological diagnosis; 2) micro-dissected human kidney tissues with clinically 
diagnosed diabetic kidney disease. 3) normal kidney tissues used as controls; 4) expression 
profiling by array OR RNA seq and raw data had the CEL format. Finally, 4 GEO datasets, 
GSE30528, GSE30529, GSE104954 and GSE50892 were included in our study. The gene 
expression data based from animal models was generated at Eli Lilly and Company disclosed in a 
previous publication [97]. All the data set that passed the initial QC inspection were imported and 
processed further by GeneSpring GX software, version 12.6 (Agilent Technologies). An R 
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language based function RMA () function available in Affy package was used to summarize raw 
expression levels. DEGs were identified with classical t test, statistically significant DEGs were 
defined with p < 0.05 and [log FC] > 1 as the cut-off criterion. 
4.2.2 Gene Ontology and Pathway Enrichment Analysis 
Candidate DEGs functions and pathways enrichment were analyzed using multiple online and 
commercial software like Ingenuity pathway analysis (IPA) and Protein Analysis Through 
Evolutionary Relationships (PANTHER). Bonferroni corrected p values of < 0.05 were considered 
significant.  
4.2.3 Statistical Analysis Software 
Except where noted above, all statistical analyses were performed in R version 3.5.1. All the DEG 
analysis and correlation density analysis were used R packages from the biocondutor.org site. The 
following R code was used to create the correlation density between gene and histopathological 
score or clinical parameters. 
# loading lib 
library(aroma.light) 
# set working dir 
setwd('C:\\Projects\\DN\\Cell_Types') 
# read in corr matrix from the dir 
d = read.table("Susztak_RNA-vs-histopath_Corr.txt", header=1, sep='\t', row.names=1) 
corr_type = 'Pearson_' 
dcor = d[, grep(corr_type, names(d))] 
dim(dcor) 
names(dcor) 
# read in genesets mapping 
genesets = read.table("Genesets_Mapping.txt", header=1, sep='\t') 
table(sort(genesets$Group)) 
cells = table(sort(genesets$Group)) 
cellnames = names(cells) 
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traits = sub('Pearson_', '', names(dcor)) 
# running parameters 
K = median(as.vector(cells)) 
N=200 
for (j in 1:length(traits)) { 
 windows() 
 #nf <- layout(matrix(c(1:6), 2, 3, byrow = TRUE), respect = TRUE)  
  
 if (j==1||j==2||j==5||j==6||j==18||j==4) { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 5)) 
 } else if (j==14||j==9||j==7||j==3||j==17) { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 4)) 
 } else if (j==8||j==11||j==13||j==15||j==25||j==24||j==23) { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 3)) 
 } else { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 2)) }  
 # "DKD2000","Renin+lisinopril","renin+PDE1i","Renin+Ucn2-16h","Renin+Ucn2-
1wk","reninAAV","Spp1_interactome" 
 cell.col = c('red','darkviolet','hotpink','aquamarine2','green', 'cyan','blue')  
  cat("Median geneset size=", median(cells), '\n') 
  ## simulating 100 times with min geneset_size 
 for (k in 1:N) { 
  plotDensity(dcor[sample(row.names(dcor), K), j], add=T, col='gainsboro') } 
 for (i in 1:length(cells)) { 
  x=names(cells[i]) 
  y=toupper(as.vector(genesets[genesets$Group==cellnames[i], 'Gene'])) 
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    plotDensity(dcor[y, j], add=T, col=cell.col[i], lwd=3, ylab='density', 
xlab=paste('Pearson correlations w/ ', traits[j], sep='')) } 
  
 if (j==1||j==2||j==5||j==6||j==18||j==4) { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 5), add=T) 
 } else if (j==14||j==9||j==7||j==3||j==17) { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 4), add=T) 
 } else if (j==8||j==11||j==13||j==15||j==25||j==24||j==23) { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 3), add=T) 
 } else { 
  plotDensity(dcor[, j], col='black', lwd=3, ylab='density', xlab=paste('Pearson 
correlations w/ ', traits[j], sep=''), ylim=c(0, 2), add=T) 
 }  
 
 legend("topleft", title='legend', c("all gene", cellnames), lwd=4, col=c('black', cell.col)) 
} 
4.3 Results 
4.3.1 Identification of common genes modulated in DKD patients 
To identify a list of genes that are modulated in DKD patients we compared the expression profile 
using several public databases. European Renal cDNA Bank (ERCB) cohort with accession 
number GSE104954, had tubulointerstitial RNA-seq data from subjects with chronic kidney 
disease and from living donor biopsies. The dataset includes a broad range of CKD patients 
including DKD patients (N=12) and living donors. In all datasets the number of DEG was 
evaluated by filtering data using a false discovery rate (FDR) of >0.05, fold induction >1.5 and 
with a p value of <0.05. We found about 5564 tubular genes are differentially expressed in the 
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DKD patient in ERCB cohort when compared to the living donors.  GSE50892 contained 
expression data from kidney biopsies of liver disease patients where the DEG was analyzed from 
9 control and 8 CKD patients and a total of 4762 DEGs were found. GSE30529 dataset provided 
expression data of micro-dissected tubules from 12 control and 10 DKD patients and GSE30528 
included RNA-seq data from glomeruli samples of 13 control and 9 DKD patients. We have found 
3401 glomerular genes and 2996 tubular genes that are differentially expressed in DKD patients 
compare to controls. To increase the likelihood of identifying genes that are modulated in DKD, 
we performed concordance analysis which is defined by the percentage of DEGs shared by the 
two platforms with agreement in the direction of fold change. As shown in the Venn diagram in 
figure 2, 5564 genes detected in the tubule data of the  ERCB cohort, 1129 overlapped with genes 
identified in the GSE30528 dataset. Only those genes showing the same direction of regulation 
whether up-regulated or down-regulated in both datasets, were further selected. This resulted in a 
set of 1081 (96%) genes with concordant expression out of 1129 total probes (Fig. 1). Similarly, 
comparingGSE30528 and GSE30529 we found 853 genes that are common in the two databases 
and 609 of them moved in same direction. Finally GSE104954 was compared to the GSE0892 
dataset and 1513 genes overlapped with a concordance of 83% (1262 genes). To compile a set of 
consensuses DEGs all the concordant genes among the three datasets were listed that resulted in 
2040 genes identified, which would be referred as DKD2000 in the subsequent analysis. The 
intersection of these concordant genes showed that there are 207 genes common in all three 
concordant gene lists (Fig 4.1).  
4.3.2 Gene Ontology analysis of DKD2000 genes 
We used Ingenuity Pathway Analysis (IPA) to conduct a comprehensive analysis and identify the 
most significantly enriched molecular functions and discover any potential novel regulatory 
networks associated with our list of genes that are differentially regulated in DKD patients using 
a criterion of Benjamini-corrected p-value of less than 0.05.  The top 10 canonical pathways based 
on the significance of the enrichment are shown in (Fig 4.2). Canonical pathways related to 
immune response was one of the most prevalent., specifically, iCOSL signaling in T helper cells 
with 27 molecules identified with a ratio of 0.407. About 63 molecules were found to be associated 
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with neuroinflammation signaling pathways with positive z score and a ratio of 0.22. Several of 
the genes pertained to the macrophage, fibroblast and endothelial cells in rheumatoid arthritis.  
 
Figure 4.1. Identification of 2040 (DKD2000) commonly changed DEGs from the four 
cohort profile data sets (GSE30528, GSE30529, GSE104954 and GSE50892). Different 
datasets were represented using different color scheme. The cross areas meant the commonly 
changed DEGs. Statistically significant DEGs were defined with p<0.05 and [logFC]>1.5 as the 
cut-off criterion and DEGs were identified with classical t-test.  
 
 Many genes were linked to the atherosclerotic signaling pathway with apparent to activity pattern 
but a ratio of 0.343. Some other pathways that are relevant to kidney diseases were the Endothelin-
1 pathway, JAK1/JAK2/TYK2 pathway and the NFAT signaling pathway. The knowledge-based 
search for associations with disease and function revealed the association of the DKD2000 genes 
with cancer, immunological disease, metabolic disease, inflammatory disease, inflammatory 
response and cardiovascular disease (Fig 4.3). Further analysis for functional annotation in 
 
 
 
111 
 
immunological disease category revealed that the majority of the genes modulated belonged to the 
systemic autoimmune syndrome which are the diseases characterized by dysregulation of immune 
 
Figure 4.2. Ingenuity Pathway Analysis (IPA) top 10 canonical pathways for DKD 2000 
DEG list. (p < 0.001). The canonical pathways identified that are most statistically significant 
are listed according to their p value (−log; orange line). Blue bars represent negative z-score; 
orange bars represent positive z-score; gray bars represent no activity pattern available. The ratio 
of the number of differentially expressed genes found in each pathway over the total number of 
genes in that pathway were represented by the orange squares. 
 
system. Although IPA analysis did not list metabolic dysregulation as one of the top disease 
functions a sub-analysis revealed several genes related to glucose metabolism disorder and 
involved in diabetic complications including DKD (Fig 4.3). A large number of genes were linked 
with the connective tissue disorder disease category and a sub-analysis revealed genes for 
rheumatoid arthritis or general arthritis are all significantly increased (Figure 4.3).  We also 
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subjected the DKD2000 gene list to Protein Analysis Through Evolutionary Relationships 
(PANTHER) which revealed a significant number of genes associated with stress response and 
immune system process (Table 2). The molecular and cellular function analysis indicated 
numerous differentially expressed genes are involved in the cell movement, cell death and survival 
and cellular morphology. 
Figure 4.3. Significantly enriched A) disease and B) function pathway analysis of the DKD 
2000 genes. 
4.3.3 Correlations between clinical phenotype and expression data in diabetic nephropathy 
To evaluate the shared contribution of differentially expressed genes towards the disease 
phenotype, we estimated the Pearson’s correlation coefficient between each gene in DKD2000 list 
and the 25 different clinical and histopathological features reported in the DKD patients (N=146 
data set as described in the methods and materials). A total of 17,000 genes were reported to be 
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present in kidney in that dataset and we measured the Pearson correlation coefficient between 
individual genes and each of the 25 different clinical and histopathological features of DKD 
patients (Fig 4.4). The correlation density curve showed a trend to zero meaning the neutral effect 
 
 
Figure 4.4. Schematic representation of the correlation density analysis of the DKD 2000 
genes. The expression of all 17K genes reported in the kidney correlations with histopathology 
data across patients. Grey lines represented bootstrapping samples (500x) in order to establish 
significant boundaries.  
 
of the genes on each of the clinical and histopathological traits.  However, when similar analysis 
was done for the DKD2000 genes, the curve shifted towards left indicating a number of genes with 
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negative correlation with eGFR whereas it showed positive shift with serum creatinine and BUN 
(Fig 4.5). Comparatively less shift was observed with serum glucose and blood pressure indicating 
a weak correlation of the DKD2000 genes with these parameters. Similar analysis was done with 
the histopathological scores of the DKD patients. Positive correlations were observed with 
Figure 4.5. Density histograms of Pearson correlation coefficient between gene expression 
signature and clinical parameters of the DKD patients. Pearson correlation coefficient was 
measured for each of the DKD2000 genes against the clinical parameters and density histogram 
was created using R script. The black line showing normal human genes and the red line showing 
DKD2000 genes. Density correlation analysis of gene set and A) GFR, B) Serum creatinine, C) 
serum glucose D) diastole and E) serum BUN. 
 
interstitial fibrosis, mesangial matrix formation, pericapsular fibrosis, arteriolar hyalinosis (Figure 
4.6). The correlation analysis showed some genes were associated with renal Kimmel Wilson 
nodules, that is the pathology hallmark of DKD. Interestingly several genes were correlated with 
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a reduced number of glomeruli. Thus, the DKD2000 genes showed good correlations with the 
several clinical and histopathological traits in DKD patients. 
 
Figure 4.6. Density histograms of Pearson correlation coefficient between gene expression 
signature and histological parameters of the DKD patients. Pearson correlation coefficient 
was measured for each of the DKD2000 genes against the A) interstitial fibrosis, B) mesangial 
matrix, C) pericapsular fibrosis, D) KW Nodules, E) glomerular number and F) mesangial 
cellularity as reported in the clinical diagnosis of DKD patients. 
4.3.4 Translatability assessment of animals to human DKD 
Earlier we demonstrated that PDE1 inhibition resulted in renal protection in an animal model of 
DKD. To evaluate the translatability of this finding to humans we conducted a similar approach 
of associating transcriptomic data to human phenotype data. To build the model we first analyzed 
the microarray data as reported in the dbdb AAV renin DKD model [190]. We identified 800 genes 
that are differentially expressed using the same criteria as before (Fig 4.7). We also found that 300 
genes were differentially expressed in the Lisinopril treated group compare to the vehicle group. 
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We identified the human orthologs of all the DEGs in both groups using the Ensembl database. 
Pearson correlation coefficient was calculated between each of the gene and 25 of the clinical and 
histopathological features of the DKD patients. As shown in figure 7 the cyan line showed that the 
density plot of the DEGs in dbdb AAV renin model shifted left like the DKD2000 genes the eGFR. 
Similarly, when correlation coefficient was calculated for some of the other clinical parameters 
like serum creatinine and BUN the correlation density plot mimicked human DKD2000 density 
plot and the lisinopril treated group demonstrated reversing those phenotype (Fig 4.7).  We 
also measured the correlation of each of the genes in AAV renin animals with the histopathological 
traits of the DKD patients to further evaluate the relationship of the molecular signature to the 
clinical histopathology. We found the density curve for AAV renin model mimicked the DKD2000 
profile for several histopathological traits of DKD. A positive correlation coefficient of greater 
than 0.5 was found for arteriolar hyalinosis, interstitial fibrosis, pericapsular fibrosis and global 
sclerosis (Fig 4.8). The DEG analysis of the microarray of PDE1 treated mice found about 836 
genes that were modulated. After deriving the human orthologs we did the same correlation 
analysis and found that PDE1 treated animals demonstrated similar shift towards to the ‘zero’ as 
seen in the normal human (Fig 6 ) for GFR, mesangial matrix and interstitial fibrosis (Fig 4.9).  
4.4 Discussion 
 By using computational biology, we identified a consensus group of DEGs that are 
common in  two other sets of DKD gene expression data and  we further confirmed the anatomical 
location of the genes using a whole kidney data set. We used IPA software suit to analyze the 
canonical ,disease and functional pathways to show that the molecular signature is predominantly 
associated with inflammation and the immune response. In the second stage we measured the 
correlation coefficient density of the consensus gene set to the 25 different histopathological 
features and some clinical parameters of DKD. Our data showed that these genes collectively 
shifted the curve that was otherwise would have remained neutral stage in normal human. We used 
two in vivo preclinical gene expression data sets and identified the human homologs. It was 
demonstrated that the gene expression changes occurring in a mouse DKD model recapitulated 
those of human DKD and standard ACE inhibitor therapy (lisinopril) or a novel PDE1 inhibitor 
shifted the Pearson’s correlation curve back to normal.  
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Figure 4.7. Model for cross species translation based on the correlation density analysis.  
A) Schematic of the model. Human orthologs of 800 mouse DEGs from AAV renin animal 
and 300 DEGs in lisinopril treated animals were derived from ensemble.org and correlation 
density as analyzed with the clinical parameters of DKD patients following the same method. 
The resulting density histogram showed the curve shifted left for B) GFR, but to the right for 
C) serum creatinine and D) serum BUN in disease state but shifted to towards to normal with 
lisinopril treatment. The black line represents normal human, ‘red’ line for DKD2000, ‘blue’ 
for renin AAV mice and ‘cyan’ for the lisinopril treated AAV renin animals. 
 
DKD is emerging as a major public health burden in the US, as 1 in 4 patients with type 2 
diabetes will develop nephropathy. Thus, the development of new therapies to treat the 
progression of DKD is a major unmet need. During the past few years, utilizing gene 
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expression profiling from renal biopsies  of diabetic  patients from has resulted in the 
identification of new therapeutic targets that enable the discovery of new drugs. In our present 
study we imported data from three publicly available GEO datasets and extract gene  
Figure 4.8. Density histograms of Pearson correlation coefficient between gene 
expression and histopathological parameters. Human orthologs of 800 mouse DEGs from 
AAV renin animal and 300 DEGs in lisinopril treated animals were derived from 
ensemble.org and correlation density as analyzed with the A)Arterial hyalinosis, B) Interstitial 
fibrosis, C) Pericapsular fibrosis, D) Global sclerosis, E) glomeruli number of DKD patients 
following the same method. The black line represents normal human, ‘red’ line for DKD2000, 
‘blue’ for renin AAV mice and ‘cyan’ for the lisinopril treated AAV renin animals. 
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Figure 4.9. Density histograms of Pearson correlation coefficient between gene expression 
and histopathological parameters. Human orthologs of 800 mouse DEGs from AAV renin 
animal and 300 DEGs in lisinopril treated animals were derived from ensemble.org and 
correlation density as analyzed with the histopathological parameters of DKD patients following 
the same method. The black line represents normal human, ‘red’ line for DKD2000, ‘green’ for 
renin AAV mice and ‘blue’ for the lisinopril treated AAV renin animals and ‘pink’ for PDE1 
treated animals. 
 
expression dataset of DKD patients in order to compare the DEGs to the living donor samples. 
The kidney is has heterogenous structure and to identify compartment specific genes, we used gene 
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expression data from the micro dissected samples of the glomeruli and tubule. We found 
expression of some of the well-known glomerular genes were downregulated in our common gene 
list. For example, NPHS1 is downregulated by 7.3 fold and NPHS2 by almost 3 fold. NPHS1 gene 
code is for nephrin, a podocyte transmembrane protein that functions both as a structural and 
signaling protein and the loss of nephrin is a sensitive marker of podocyte injury. It has been 
reported that in DKD patients nephrin mRNA and protein is downregulated [191]. NPHS2 codes 
for podocin which is located onthe cell surface in the area between two podocytes called the slit 
diaphragm. In a cross functional study of a few DKD patients found that both podocin and nephrin 
protein expression are downregulated in the kidney biopsies [192]. Moreover in a separate study 
urinary podocin level was higher in DKD patients with very low GFR [193]. Some other podocyte 
specific genes like WT1, SLIT2 and PODXL [189] were also found to be down regulated, overall 
indicating poor health of the podocytes in DKD. Several known tubular specific genes like 
SLC4A1, MME2, HNF1B and FBPI also were differentially expressed in the DKD patients [189].  
Canonical pathway analysis indicated that the consensus genes in DKD2000 list mostly involved 
in the inflammation and immune response. We found the top five canonical pathways are 
associated with helper T cell, macrophage and dendritic cell biology.  The top pathway based on 
the p value is  iCOS/iCOSL signaling pathway, that involves  inducible co-stimulatory molecule 
(ICOS) and ICOS ligand (ICOSL) which is critical in T cell activation and survival, particularly 
in T cell dependent humoral immunity [194].   Helper T cells are activated when exposed to 
antigens presented by such as dendritic cells, B cells, and macrophages which in turn orchestrates 
the adaptive immune response. Several studies have provided evidence that both Th1 and Th2 
responses requires ICOS to preferentially stimulates the production of Th2 cytokines IL-4 and IL-
10 [195]. In lupus nephritis both early and late blockade of ICOSL improved clinical signs [194]. 
Traditionally DKD is not considered “immune-mediated” form of kidney disease but recent data 
from both gene expression and experimental studies supports involvement of many immune 
system components during DKD progression. In an animal model of DKD, it has been 
demonstrated that the initial infiltration of T helper cells facilitates the later wave of macrophages 
and cytotoxic T cell, thereby suggesting a Th1-driven response [196]. We found a number of genes 
are linked to the signaling pathway of macrophages, fibroblast and endothelial cells in Rheumatoid 
arthritis. Baricitinib, a selective JAK1/2 inhibitor, demonstrated significant efficacy in the 
treatment of rheumatoid arthritis. In a phase 2 trial of DKD patients, this drug has demonstrated 
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significant reduction of albuminuria along with reduction of several inflammatory biomarkers in 
the plasma and urine. This supports our findings that the signaling pathway in rheumatoid arthritis 
plays a role in the pathophysiology of DKD. Our subsequent disease and function analysis along 
with upstream pathway analysis further support that the inflammation pathway is dominant in 
DKD. We found that injury and tissue abnormalities, and inflammatory response are among the 
top 10 disease categories and the major upstream regulators were INF- and TNF. 
Analysis of transcriptional changes helps to understand disease progression, but a critical 
limitation is it cannot establish a causal relationship between the altered expression of genes and 
pathophysiological responses [197]. In an order to evaluate the functional significance of these 
DEG, an unbiased measurement of the association between the clinical and histopathological 
features of the clinically diagnosed DKD patients was undertaken. Our correlation density analysis 
with the clinical parameters demonstrated that the gene sets collectively shifted the Pearson’s 
correlation curve left indicating a negative effect on eGFR. Some of the genes that showed strong 
correlation with eGFR included WFDC2, PAPPA2, ADAM28 and RGS10 and they were 
previously associated with kidney disease. WFDC2 encodes a protein with a highly conserved 
whey acidic protein domain (WAP) – which is a known biomarker for ovarian carcinoma. and the 
WFDC2 protein was identified in tumor tissue, urine and serum. In a mouse model of acute kidney 
fibrosis, it has been shown that WFDC2 expression is high and correlated with tubulointerstitial 
fibrosis. High expression of WFDC2 has been reported in kidney biopsies of CKD patients [198]. 
We report for the first time reported its negative association with eGFR and also show a strong 
correlation with interstitial fibrosis in DKD patients. Similarly, macrophage gene MSR1 codes for 
a multifunctional scavenger receptor. Genetic deletion of MSR1 has been shown to be protective 
in streptozotocin induced mouse DKD by inhibiting the macrophage migration into the  kidney 
[199]. Our analysis demonstrated MSR1  had a strong negative correlation with eGFR and positive 
correlation with interstitial fibrosis. In addition, we found both LCN2 and Sox9, two well-known 
markers for tubular injury strongly correlated with interstitial fibrosis. This type of corroborating 
evidence validates our method. Correlation analysis between structural features derived from 
whole slide images of tissue samples and gene expression data  has been used to identify many 
biological pathways that are strongly associated with cancer [200, 201]. Our initial analysis also 
found some new as well as some known genes that strongly correlated with the DKD phenotype. 
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Using our gene expression to phenotype correlation model, we showed that the gene expression 
signature well correlated with some of the hallmark features of the DKD such as eGFR, interstitial 
fibrosis or mesangial matrix.  Cancer gene signatures have been used to predict radiation response 
[201]. Similarly,  mouse CKD studies have shown a unique molecular signature  that recapitulates 
pathophysiological mechanisms of  CKD and human orthologs of the mouse genes can be used to 
predict eGFR in humans at various stages of CKD [202]. We tried similar approach to predict the 
translatability of our PDE1 animal study to human DKD. We first validated our approach using 
gene expression database from untreated and lisinopril treated AAV renin overexpressed dbdb 
uninephrectomized mice [190]. DEG analysis of the microarray data showed 800 genes modulated 
in this disease model. When we analyze the data in our unbiased statistical model it demonstrated 
a similar pattern in the correlation density analysis as seen with human DEGs. For instance, the 
mouse molecular pattern showed a strong negative correlation with eGFR and positive correlation 
with interstitial fibrosis, mesangial matrix and some other features of human DKD histopathology. 
The lisinopril treated mice gene expression data shifted the curve more to the neutral position as 
seen in the normal humans. The dbdb AAV-renin model has been shown to have many 
physiological features of advanced human DKD like robust proteinuria, reduced GFR, and 
increased serum creatinine and lisinopril has been shown to be beneficial in this model [97, 190]. 
Moreover, lisinopril and related drugs are widely used as standard of care in the clinic for DKD 
patients. This analysis provides some validation of our model for translatability of mouse  to human. 
Importantly, the DEGS from the PDE1 treated dbdb renin AAV DKD model  similarly shifted of 
the disease molecular signature towards normal human, thus suggesting higher potential of  renal 
protection translating to human DKD.  
There are some limitations of this study. We have combined both microarray and RNA-seq data 
sets to do our analysis which might have resulted in loss of a few genes. RNA-Seq and microarray 
are the most commonly used high-throughput technologies for transcriptome profiling, each with 
their own inherent strengths and limitations. However Chen et al. reported that for most transcripts 
within the same tissue, the results obtained by RNAseq and microarrays were highly reproducible 
[203].  The other potential limitation is that we did not demonstrate the statistical significance of 
the relationship for our correlation density measurement. enough statistical power to demonstrate 
the confidence of the correlation density data. The patient cohort used in this study did not have 
large number of samples. Moreover, there was no simulation run with the correlation coefficient 
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to determine the significance of this relationship. More study is needed to determine the 
significance of this finding. At this stage our efforts should be deemed exploratory and require 
further refinement.  
 In summary we have found a consensus set of renal DEGS in multiple DKD patient cohorts 
and demonstrated that the expression signature is associated with inflammation and immune 
response. We also developed a molecular phenotype model to show that the renal gene expression 
signature strongly correlated with the histopathological and clinical features of DKD patients. The 
trend to normal human gene expression in in lisinopril treated DKD mice, suggested that this model 
has the potential to predict the progression of human kidney disease and thus estimate the likely  
the outcome for novel therapeutics.  
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 GENERAL CONCLUSION 
By 2035 it has been estimated that the number of diabetic patients worldwide will reach about 593 
million and with a ¼ of them progressing to the end stage renal disease and it is conceivable that 
a major medical and economic burden of DKD will occur in the future. In clinic, the treatment of 
diabetic kidney disease (DKD) is still mainly based on control of hyperglycemia and blood 
pressure, as there is no other validated and novel therapies able to halt the progression of renal 
failure. Several clinical trials controlling both blood pressure and/or or hyperglycemia already 
established modest renal protection, however these approaches are not enough to stop the 
progression of DKD. The role of intensive glycemic control in treating DKD is controversial. Two 
large observational trials, Diabetes Control and Complications Trial (DCCT) in T1DM and the 
United Kingdom Prospective Diabetes Study (UKPDS) could not provide a clear-cut HbA1c 
threshold in T2D patients, only further confirming that there is a strong relationship between 
glucose control and the risk of the development of diabetic microvascular complications. A more 
sophisticated designed trial called ADVANCE, included patients with a high HbA1C levels, but it 
also demonstrated no significant relationship between renal protection in T2D patients with 
Hb1AC levels of 6.5% [204]. Moreover, the imprecision of HbA1C measurements and undesirable 
pharmacokinetics of some recent promising antidiabetic drugs, makes their use in glycemic 
management in patients with DKD complicated. Despite the success with an SGLT2 inhibitor in 
slowing DKD, thetrial indicates the limitations their use  in renal impaired patients due to 
hypovolemia, ketoacidosis and hyperkalemia as issued by the FDA [205]. 
 
The mechanisms responsible for the development and progression of DKD remain incompletely 
understood. In the past several years there has been tremendous advancement in understanding 
several downstream signaling pathways that are triggered by the interplay of hemodynamic and 
metabolic factors of T2D. Chronic hemodynamic and metabolic changes as a result of prolonged 
exposure to systemic risk factors like high glucose or overactive RAAS can modulate various 
intracellular signaling pathways, transcription factors, cytokines, or growth factors that can 
ultimately promote structural abnormalities in the kidney, such as basement membrane thickening, 
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podocyte injury, and mesangial matrix expansion, glomerular sclerosis and tubulointerstitial 
fibrosis all of which associate with declining GFR [2, 10]. Despite some understanding of these 
signaling pathways causing DKD, it is less clear how risk factors activate of intracellular signaling 
pathways.  
 
This thesis attempts to establish this connection. We provided a synopsis of how external stimuli 
activate cell surface receptors, generating secondary signals inside the cell to alter TRPC calcium 
channel function, calcium sensitive PDE1 and the downstream cyclic nucleotides that affect the 
progression of DKD. In our first chapter we used a potent and selective PDE1 inhibitor to address 
its hemodynamic properties and its potential to protect diabetic nephropathy. The vasodilatory 
properties of PDE1 inhibition has been featured in many publications but its effect on systemic 
hemodynamics has not been reported until very recently [50-52, 55, 101, 103]. Using a potent pan 
PDE1 inhibitor we have demonstrated vasodilation in vivo by adopting a novel technique using 
elevated ear temperature as surrogate marker for peripheral vasodilation which resulted in 
lowering of blood pressure in both normotensive and hypertensive rats. This prompted us to 
investigate PDE1 inhibitor’s role in the context of renal disease as anti-hypertensive drugs have 
shown to be reno-protective. Moreover, PDE1 is highly expressed in both glomeruli and tubule 
[58] and preservation of cyclic nucleotide has been found beneficial for kidney [23, 43, 93], 
suggestion a direct renal protective role as well Indeed, we demonstrated for the first time that 
PDE1 inhibition leads to the renal benefit using a rodent model of DKD as evident by lowering of 
ACR, serum creatinine and several urinary biomarkers of kidney injury. The histopathological 
improvements due to PDE1 inhibition were associated with and likely driven by inhibition of 
inflammation and fibrosis pathways. Using gene expression analysis of CKD patients, we 
identified TRPC6 as major calcium channel that is upregulated in the glomeruli and, using human 
primary mesangial cell and rat isolated glomeruli, we have shown that induction of TRPC6 activity 
leads to apoptosis in PDE1 dependent manner. In next section we asked the question of how 
TRPC6 gets activated in the diabetic environment, that is to focus on the upstream signaling 
pathway.  
 
In the second chapter we have elucidated certain aspects of upstream activation of TRPC6 in a 
context of metabolic disturbances. Elevated level of calcium, DAG and ROS are all thought to 
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contribute to the pathogenesis of DKD. Elevated levels of angiotensin II and ET-1 in diabetic 
patients is known [[206]63]. Both can contribute to the activation of TRPC6. Our studies for the 
first time connected the diabetic risk factors with activation of TRPC6 and demonstrated a 
crosstalk between two second messengers, calcium and cyclic nucleotides. In connection to our 
earlier pre-clinical finding of renal benefit upon PDE1 inhibition, here we provided mechanistic 
evidence of activation of PDE1 by the systemic risk factors that involves TRPC6. One of the 
limitations of this study is the lack of either pharmacological or genetic evidence of involvement 
of PDE1 in the depletion of cAMP. Although we showed that hyperforin mediated increase in 
calcium is TRPC6 specific, the depletion of cAMP could be due to non-specific action of 
hyperforin. Further studies are required to show the specificity of hyperforin 9 with selective 
inhibitors of TRPC6. The lack of reliable cGMP biosensor also precluded us from investigation of 
potential mechanistic link between TRPC6, PDE1, and cGMP. More research is needed to 
interrogate this pathway. However, our data still provide sufficient evidence of a crosstalk between 
TRPC6 and PDE1 and their potential role in pathogenesis of DKD. 
 
In this context of pathophysiology of DKD it is not surprising to see that the successful drugs in 
DKD are those that interfere with inflammation, fibrosis and hemodynamic pathways. Both 
canagliflozin (SGLT2 inhibitor) and atrasentan (ETA receptor antagonist) demonstrated their 
renoprotective effects in large clinical trials that were associated with  lowering of systolic and 
diastolic blood pressures [13, 90]. Moreover, ET-1 has been linked with renal inflammation and 
ETA receptor blocker showed reduction of proteinuria by reducing inflammation. In this regard 
PDE1 inhibition seems to be an ideal candidate to treat DKD as it demonstrated its vasodilatory 
and anti-inflammatory and anti-apoptotic features in a pre-clinical model of DKD. The dbdb renin 
AAV model of diabetic nephropathy has been shown to demonstrate several human DKD features 
[97, 190], however translation of these results to human DKD remains to be determined. To tackle 
this translation problem, we utilized computational biology, analyzed gene expression data of 
DKD patients and correlated it with clinical parameters and renal histopathology of DKD patients 
to develop a predictive model. 
 
Thus, the focus of the third chapter was to correlate human kidney gene expression to physiological 
and histopathology phenotypes and develop a statistical model to assess the preclinical DKD 
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treatments outcomes on gene expression with that observed in humans. While DKD is not regarded 
as a exclusive form of “immune-mediated” kidney disease, recent gene expression data from DKD 
patients and several preclinical data supports involvement of many immune system components 
in DKD progression. Our findings in DKD2000 gene pathway and disease analysis is in line with 
recent reports [207]. Our gene expression to phenotype model showed that the gene signature 
strongly correlates with the histopathological and clinical features of DKD patients. Using the gene 
expression data set from untreated and  lisinopril treated mice with DKD,  showed a high level of 
correlation with normal and diseased human DKD This model could be used to predict the human 
outcome  since the murine gene expression changes with the PDE1 inhibitor overlapped with the 
human data set.  
 
Overall the contents of this thesis demonstrated a new unique biology connecting calcium and 
cyclic nucleotides, the two important intracellular messengers in the progression  of DKD . In 
addition, an exploratory effort using bioinformatics provided some evidence of the clinical 
relevance of our findings.  
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